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C-end binding by TPR co-chaperones links proteolysis and 
protein homeostasis 
By Matthew Anthony Ravalin 
Abstract: Proteolysis is unique among post translational modifications because it is 
irreversible. The specific recognition of protein termini is an essential mechanism by 
which proteolytic enzymes mediate signaling in biology. The identification of terminal 
recognition elements with complimentary specificity to proteases, often as part of a E3 
ubiquitin ligase, has facilitated the elucidation of protease signaling pathways that 
function in critical cellular processes. The caspase family of protease are well known for 
their role in directing the fate of the cell by initiating and executing inflammatory and 
death-related signaling cascades. The biochemical feature that unites this family of 
enzymes is the ability to hydrolyze a peptide bond following and aspartic acid. We have 
determined that the TPR family of co-chaperones, including the E3 ubiquitin ligase 
CHIP, can also bind to a subset of new C-termini generated by caspase activity. These 
co-chaperones were though to function predominantly, if not exclusively, by interacting 
with a conserved Glu-Glu-Val-Asp at the C-terminus of cytosolic Hsp70s and 90s.  This 
work has uncovered new functions for both caspases and TPR co-chaperones and has 
identified a dedicated molecular framework for caspases and protein homeostasis 
networks to exchange information. These systems play a critical role in balancing cell 
fate in development and disease making it likely that critical signaling nodes occur at 
this interface. 
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Chapter 1 
 
End-Binding E3 ubiquitin ligases enable protease signaling 
Matthew Ravalin, Koli Basu, Jason E. Gestwicki and Charles S. Craik 
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Abstract. The modular recognition of post-translational modifications directs the 
assembly of macromolecular complexes in cells. This mechanism is indispensable for 
signaling events critical to all life. Proteolysis is a unique PTM because it is irreversible 
and generates two protein products in the form of a nascent N and C terminus. This 
distinction from other PTMs underscores unique challenges and opportunities in the 
study of proteolysis as a signaling modality. We highlight the critical biological function 
for end-binding E3 ubiquitin ligases that specifically engage in protein-protein 
interactions with the termini that arise from proteolysis. These interactions potentiate 
proteolytic signaling by tuning the duration and magnitude of signaling events, a role 
fulfilled by the catalysis of PTM removal in other systems. We describe recently 
characterized examples wherein biological functions depend on these interactions and 
formalize a conceptual framework within which to parse these pathways to elucidate the 
biology they direct.  
 
1.The unique attributes of proteolysis as a PTM. The biophysical underpinnings of 
protein-protein interactions (PPIs) are diverse.1,2 Among PPIs, those that occur between 
a globular protein domain and a peptide have garnered significant interest because of 
the role they play in signaling and their amenability to chemical modulation.3,4 This class 
of PPI is often regulated by post-translational modifications (PTMs). When this is the 
case, the formation of the PPI is a composite readout of the activities of the PTM 
placing (E) and removing enzymes (E*), as well the specificity of the PTM-binding 
modular recognition element (MRE).5 This framework has been widely employed in the 
study of chromatin modification. In these signaling networks the interplay between 
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readers (MREs), writers (E), and erasers (E*) directs chromatin state and the 
transcriptional landscape of the cell.6,7 The development of chemical probes for the 
components of these networks has facilitated a better understanding of the biology they 
direct.8 
 Proteolysis, the hydrolysis of an amide bond in a polypeptide chain, is a unique 
PTM because it is irreversible, and thus represents a committed biological step. Given 
this irreversibility, proteolytic signals exist in flux rather than in a dynamic equilibrium.9,10 
Each proteolytic event generates two products, a nascent N and C terminus with 
opposing charges (Figure 1.1A). Proteolytic activity ranges from complete degradation 
to limited cleavage. It is capable of transmitting signals by removing whole domains, 
facilitating the maturation of structural features,  destroying entire proteins, or by 
removing a single amino acid.11 The way to recover the function of a cleaved protein is 
through re-synthesis. Conversely the way to remove the function of cleavage products 
is though degradation. This feature positions the cellular effectors of protease product 
stability at a critical regulatory node for proteolytic signaling. The ubiquitin proteasome 
system (UPS) is a major pathway for protein degradation in eukaryotes.12 Generally, the 
propensity for a protein to be degraded by the UPS is controlled by its ubiquitination and 
delivery to the proteasome. The specificity of ubiquitination and degradation in the cell is 
controlled by the activity of the 500-1000 E3 ubiquitin ligases expressed in mammals.13 
A subset of these E3 ubiquitin ligases recognize protein termini (i.e. are end-binding) 
and are poised to regulate the stability of the products of proteolysis (Figure 1.1B and 
Figure 1.1C).14,15 
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2. Shared specificity links proteolysis and E3 function. The unique features of 
proteolysis as a PTM have enabled the evolution of signaling cascades that exploit it as 
a means of transmitting information.16 Indeed, biological processes rooted in proteolysis 
are ubiquitous in living systems. Additionally, links between terminal recognition and 
protein degradation have been characterized in bacteria, plants, yeast, and mammals.17 
In eukaryotes E3 ubiquitin ligases that contain a terminal recognition element (TRE) 
couple the terminal chemical composition of a polypeptide substrate to its degradation. 
An implicit connection between a protease and E3 ligase arises from the physical 
interaction of each with a shared substrate. The strength of this connection depends on 
the overlap of the specificity of each (Figure 1.1D). Explicitly, a link between a protease 
and a C-end binding E3 depends on the complementarity between the C-end TRE and 
amino acids N-terminal to the cleaved bond (the non-prime sites). Accordingly, the link 
between a protease and an N-end binding E3 depends on the complementarity between 
the N-end TRE and the amino acids C-terminal to the cleaved bond (the prime sites) 
(Figure 1.1E). Given that product degradation is a regulator of protease signaling flux, 
the development of a comprehensive understanding of protease-E3 crosstalk is likely to 
identify regulatory nodes in protease signaling. A key challenge in understanding the 
role of proteases in biological processes is the differentiation of functional substrates 
from bystanders (i.e. cleavages that yield no change in function). Focusing on cleavage 
events coupled to subsequent end-binding E3 activity may facilitate the prioritization of 
functional cleavages. With this framework in hand we can hope to leverage an 
understanding of the specificity of proteases and end-binding E3 ubiquitin ligases 
determined in vitro to illuminate biological signaling pathways in vivo. 
	 5 
 
3. N-degrons tune protease substrate function. A degron is a protein feature that 
potentiates the degradation of a given substrate. A N-degron is such a feature that is 
present at the extreme N-terminus of a polypeptide. In total, the N-degron pathways link 
in vivo protein stability to the physiochemical properties of the N-terminus of a 
polypeptide.18 N-degron pathways are present in prokaryotes and eukaryotes.  In 
eukaryotes, these pathways were classically divided into two arms. In the Ac/N-degron 
pathways, protein degradation is trigged by the recognition of an acetylated N-terminal 
sequence by dedicated E3 ubiquitin ligases.19 The bulk of eukaryotic proteins are 
irreversibly acetylated co-translationally.20,21  Acetylation can be preceded by the 
removal of the N-terminal Met generated by the start codon via the activity of 
methionine aminopeptidases (MetAPs).22,23 The convolution of mRNA encoded N-
terminal sequence, acetylation, and demethionylation impart newly translated proteins 
with the ability to adopt an array of physiochemical features at the N terminus. The 
propensity for an encoded N-terminal sequence to be acetylated or demethionylated is 
dictated by the specificity of the MetAPs and N-terminal acetylases. It general, the 
removal of methionine from the N-terminus is favored in instances when a sterically 
small (Ala, Val, Ser, Thr, Cys, Gly, and Pro) residue is present at the position directly 
adjacent to the N-terminal Met. N-terminal acetylation is favored for all of these residues 
with the exception of Gly and Pro.24 
 The other classical arm of the N-degron pathways are the Arg/N-degron 
pathways. In this arm, N-termini bearing positively charged (Arg, Lys, His, e.g. Type I 
degrons) or large hydrophobic (Leu, Phe, Trp, Tyr, Ile, e.g. Type II degrons) are 
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ubiquitinated by a subset of the UBR family of E3 ubiquitin ligases (UBR 1, 2, 4, and 5 
in mammals).25 These E3 ligases depend on the specific recognition of the positively 
charged N-terminal amine to bind to their substrates. Type 1 degrons are recognized by 
the UBR domain that contains a binding site capable of coordinating the positive 
charges of both the N-terminus and the side chain of the N-terminal Arg, Lys, or His 
(Figure 1.2A).26 The structural aspects of the recognition of Type II degrons is less 
understood, however a discrete recognition domain in UBR1 and UBR2 is responsible 
for binding these sequences.27 This domain is homologous to a TRE found in bacteria, 
ClpS, which binds to N-terminal hydrophobic and aromatic amino acids, directing 
degradation by ClpXP (Figure 1.2B).28 Collectively, N-termini that are directly 
recognized and ubiquitinated by the UBR E3s without being modified are referred to as 
“primary” N-degrons.  
Some N-termini require chemical modification prior to being shunted through the 
Arg/N-degron pathways. For example, N-terminal Asp and Glu residues must first be 
modified with an N-terminal Arg by the Ate family of Arg transferases.29 Given the 
necessity for a single modification to sequences bearing terminal Asp and Glu residues 
they are referred to as “secondary” degrons. N-terminal Cys residues require oxidation 
by nitic oxide prior to argenylation by Ate.30 N-terminal Asn and Gln are converted to 
Asp and Glu respectively via side-chain deamidation by Ntaq1 before argenylation can 
occcur.31 As they require two modifications prior to recognition by the Arg/N-degron E3 
ligases, sequences bearing terminal Cys, Asn, or Gln are referred to as “tertiary” 
degrons. The generation of secondary and tertiary degrons by proteolysis decouples the 
link between protease and TRE specificity so that the sequences generated by 
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proteolysis must be considered in the context of the intermediary activity of the 
additional enzymes necessary to produce a UBR binding sequence. A poignant 
example of this logic is evident in the processsing of the Ubiquitin specific peptidase 1 
(USP1). USP1 auto-proteolyzes to yield a nascent N terminus bearing a conserved Gln 
residue. The degradation of this USP1 fragment requires the activity of both Ntaq1 and 
Ate1.32 Therefore, although USP1 does not generate a N-terminal Arg directly, its prime-
side specificity still links it to the UBR E3 ligases. 
 Although N-degron pathways were first described over thirty years ago, facets of 
the biological functions they direct are still being uncovered. Given the propensity for N-
terminal Gly and Pro residues to be generated by MetAP activity but resist acetylation 
and degradation by both the Ac/N-degron Arg/N-degron pathways, the fate of these N-
termini has remained a mystery. Recently it was discovered that GID4, a component of 
the GID E3 ubiquitin ligase complex in S. cerevisiae specifically bound proteins bearing 
a free N-terminal proline and shunted them to the UPS.33  This pathway proved critical 
for the rapid degradation of gluconeogenic enzymes when S. cerevisiae were 
transitioned from acetate or ethanol-based growth media to glucose-based media. 
Further work provided structural and biophysical evidence that demonstrated that 
human GID4 specifically recognized N-terminal proline and required a free amine at the 
N-terminus (Figure 1.2C).34  
An N-degron pathway for unacetylated Gly residues has also recently been 
described. Briefly, a functional genomics screen identified Cul2ZYG11b and Clu2ZER1, as 
the E3 ubiquitin ligase complexes responsible for the degradation of N-terminal Gly 
bearing polypeptides.35 An analysis of the specificity of degradation determined that the 
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presence of a proximal Phe, Gly, His, Leu, Met, or Tyr residue favored degradation. 
These Gly N-degrons were depleted in the native human proteome but enriched in the 
N-termini produced by caspase cleavages. Furthermore, N-myristoylation of N-terminal 
Gly was shown to compete with E3 ligase activity so that proteins or protein fragments 
bearing N-terminal Gly which do not readily undergo myristoylation and subsequent 
membrane localization are likely to be destroyed through this N-degron pathway. When 
considered in context with previous data indicating that N-degrons are conserved in 
toxic caspase-generated fragments, this data points to intricate crosstalk between 
caspase activity and N-degron pathways.36 
Considering the importance of limited proteolysis to cell health, it is not surprising 
that pathogens employ limited proteolysis to hijack degradation pathways. It was 
recently demonstrated that the mechanism of cell killing for Anthrax Lethal Factor (LF), 
a secreted virulence factor from Bacillus anthracis, depends on the N-end rule E3 
ubiquitin ligases UBR2 and UBR4. It was known that cell killing by LF depended on the 
activation of the NLRP1B inflammasome.37,38 LF is a metalloprotease that is trafficked to 
the cytosol where it cleaves the N-terminus of NLRPB1 between Lys44 and Leu45, 
creating a type-II Arg/N-degron. NLRP1B exists as an autoinhibited heterodimer that 
arises from autoproteolysis in the FIND domain of the protein. The unmasking of Leu45 
at the N-terminus by LF destabilizes the autoinhibitory fragment, leading to the 
oligomerization of the NLRP1B CARD (CAspase-Recruitment Domain) domain 
containing fragment, the activation of caspase-1, and pyroptosis. In essence, an effector 
reprograms the stability of a host protein via proteolysis to elicit a cellular response that 
favors pathogenesis. Given that many pathogens have evolved proteolytic effectors, it 
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seems probable that reshaping host protein stability in this manner is common at the 
host-pathogen interface. 
 
4. The IAP N-end-binding E3s regulate caspase activation and activity. As 
proteolysis is irreversible, the regulation of protease activity is often redundant and 
multi-faceted. Many proteases are produced in a zymogen form to restrict the context of 
their activity.39 These proteases must mature into an active enzyme prior to efficient 
cleavage of their biological substrates. This maturation usually requires proteolysis such 
that the active enzyme contains N and/or C termini not present in the zymogen. The 
caspase family of cystine proteases are well understood in this respect. The 
inflammatory caspases (-1, -4, and -5 in humans) and initiator caspases (-2, -8, -9, and -
10), must dimerize through scaffolding interactions with the CARD or death effector 
domains (DED) present at their N-terminus prior to maturation.40 This scaffolding is 
mediated by signaling events that cue the assembly of multicomponent complexes (i.e. 
inflamasome, apoptosome, DISC complex, etc.) which facilitate dimerization through 
these accessory domains. Upon dimerization, autoproteolysis leads to the release of the 
mature enzyme bearing new N and C termini on both the large and small subunits. The 
executioner caspases (-3, -6, and -7) exist as constitutive homodimers in their zymogen 
form. Maturation is canonically induced by the activity of initiator or inflammatory 
caspases and subsequent maturation via the proteolytic excision of the pro-domain and 
the inter-subunit linker.41 
The maturation of caspases -3, -7, and -9 yields a new N-terminus on the small 
subunit that engages in a regulatory interaction with the X-linked inhibitor of apoptosis 
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(XIAP). This E3 ubiquitin ligase consists of three Baculovirus IAP Repeat (BIR) domains 
and a RING domain which mediates the formation of a homodimer. BIR1 is devoid of 
caspase binding activity and seems to support dimerization.42 BIR2 mediates the 
inhibition of the active forms of caspases -3 and -7. This activity depends on the 
capacity of the peptide linker region between BIR1 and BIR2 to occupy the active site of 
the caspase in a reverse orientation relative to substrate.43,44 This orients Asp148 so 
that it occupies the S1 subsite. This binding mode is supported by the ability of the BIR2 
domain to bind to the new N-terminus of the small subunit generated during maturation 
(Figure 1.3A). Coordination of the N-terminus is mediated by Asp214 and Glu219 in the 
BIR2 Domain. Structural and mutagenesis studies have confirmed that both the end-
binding activity and substrate mimicry are important for BIR2 inhibition of caspase-3 and 
caspase-7.45 The BIR3 domain mediates the inhibition of caspase-9 in a similar fashion, 
with the distinction that binding of the N-terminus of the small subunit is sufficient to 
inhibit activity (Figure 1.3B).46 Although the role of the RING domain and ubiquitin 
ligase activity of XIAP in regulating caspase degradation remains unclear, it is clear that 
the end-binding activity of XIAP is critical for directing cell fate..  
 XIAP deters the activity of caspases that may lead to undesirable programmed 
cell death. Accordingly, this activity is neutralized during apoptosis. This is achieved by 
the generation of nascent N-termini that compete with caspases for the N-end binding 
sites in XIAP. IAP Binding Motifs (IBMs) are present at the nascent N-termini of proteins 
released from the mitochondria during apoptosis.47 These proteins include Smac, 
HTRA2, and PGAM5 among others. The most extensively characterized of these 
proteins is Smac (Second mitochondrial activator of caspases). In a healthy 
	 11 
mitochondrion, Smac is tethered to the inter-membrane by an N-terminal 
transmembrane anchor. Upon outer-membrane permeabilization, Smac is cleaved by 
the integral-membrane metalloprotease PARL.48 PARL cleavage imparts SMAC with a 
nascent N-terminus (NH2-AVPI) capable of binding BIR2 and BIR3 in XIAP (Figure 
1.3C and Figure 1.3D).49,50 Smac dimerizes upon release and diffuses into the cytosol 
where it sequesters XIAP and potentiates the propagation of caspase signaling 
cascades. In total it is the interplay between IBM motif generation and the binding 
partners they engage with that tunes the probability of a cell surviving or undergoing 
programmed cell death. The Smac-IAP axis has proven amenable to the generation of 
peptidomimetic chemical probes with activity in cells and in vivo.51 Medicinal chemistry 
efforts have yielded multiple scaffolds with degrees of selectivity for different BIR 
domains among the IAPs with the goal of potentiating cell death for the treatment of 
cancer.52 The coupling of PARL and XIAP function by Smac serves as an effective 
exemplar for the molecular logic that underpins substrate-linked functional interactions 
between proteases and end-binding E3 ligases. The competition between caspases and 
cleaved Smac for XIAP effectively links the two signaling modules and creates a higher-
order signaling network (Figure 1.3E). 
 
5. C-degrons: new opportunities in protease signaling. Until recently, knowledge of 
end-binding E3 ubiquitin ligases was largely restricted to E3s with the capacity to 
recognize an N-terminus. In 2018 Koren et al and Lin et al used global protein-stability 
(GPS) profiling and CRISPER-based functional genomics screens to systematically 
identify C-degrons and match said degrons to the components of the UPS that 
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mediated their degradation.53–55  This global cellular profiling effort led to the 
identification of eleven C-end binding E3 ubiquitin ligases with unique specificities that 
mediate degradation. The bulk of the E3 ligases identified were of Cullin-RING E3 
ligases (CRLs e.g. Cul2 or Cul4) bound to adaptors that mediated C-end binding. All 
identified adaptors contained repeats of protein domains that form solenoids (Kelch, 
Ankyrin , Tetratricopeptide, WD40, and Armadillo-like repeats). Structures of the Kelch 
domain adaptor KLHDC2 bound to C-degron sequences were solved by Rusnac et al.56  
These studies identified the molecular determinants of C-end binding in this adaptor to a 
Gly-Gly sequence at the C-terminus (Figure 1.4A and Figure 1.4B). One such Gly-Gly 
C-end degron in USP1 arises from the same autoproteolytic cleavage event that also 
generates a tertiary Type-1 N degron (via an N-terminal Asn residue). This coincidence 
of N and C degron pathways on a single cleavage site highlights the amount of 
information that can be irreversibly unmasked by a single proteolytic event (Figure 
1.4C). 
The regulatory logic of C-degron pathways is likely quite different from N-degron 
pathways. Free C-termini are far more abundant than free N-termini in the cell. While C-
terminal modifications including methylation, amination and adenylation occur, they are 
generally transient or limited to specific biochemical or cellular context.57 Additionally, 
the specificity of soluble proteases is often dominated by the non-prime substrate 
specificities. This makes the identification of co-evolved protease and C-end binding E3 
ligase specificities more likely, even absent knowledge of physiological substrates. 
Further work is required to understand the molecular and cellular determinants of C-
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degron pathway function and to what degree they are shaped by proteolysis and other 
PTMs.  
 
6. Crosstalk between the C-end binding E3 ligase CHIP and caspases. Few E3 
ubiquitin ligases containing C-end TREs had been identified prior to the discovery of the 
C-degron pathways mentioned above. The carboxy terminus of Hsp70 interacting 
protein (CHIP) was among few with annotated specificity and function. CHIP is a Ubox 
domain-containing E3 ubiquitin ligase that forms a homodimer.58,59  In addition to the 
Ubox domain CHIP also contains a tetratricopeptide repeat (TPR) domain at its N 
terminus. The TPR domain binds to a conserved motif at the C-terminus of cytosolic 
Hsp70s (IEEVD-CO2H) and Hsp90s (MEEVD-CO2H) in eukaryotes. (Figure 1.5A) This 
PPI positions CHIP to facilitate transfer of ubiquitin from E2 to a chaperone-bound 
client. (Figure 1.5B) Specificity for the terminal Asp residue is achieved through a 
conserved carboxylate clamp consisting of two Lys residues that form a bidentate 
interaction with the negatively charged carboxylates.60,61  In addition to the coordination 
of the C-terminal Asp at P1, interactions with the Ile or Met at P5 and the Val at P2 are 
also critical for chaperone binding.62 CHIP has been attributed with a wide array of 
cellular functions. The presumption in a majority of these cases has been that CHIP is 
functioning in cooperation with cytosolic chaperones.  While the degradation of multiple 
chaperone clients has been attributed to CHIP function, a wholistic model of CHIP 
regulation has remained elusive. For example, it has been shown that mono-
ubiquitination of CHIP is essential for it to be “active” and degrade aggregation-prone 
mutants of Huntington.63–65 The absence of monoubiquitinated CHIP in neurons is 
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thought to mediate neuron-specific selective vulnerability to Huntington toxicity relative 
to astrocytes which contain a pool of monoubiquitinated CHIP. Additionally, it has been 
shown that in the context of cellular stress CHIP can repartition to the membrane or 
mitochondria.66,67 In short it seems that the regulation of CHIP activity is far more 
complex than the model wherein CHIP binds to the C-terminus of chaperones and 
potentiates the degradation of their clients by ubiquitination. 
We recently reported that the CHIP TPR domain was capable of interacting with 
a far broader range of C-termini than previously thought.68 Briefly we used a positional 
scanning synthetic combinatorial library (PSSCL) of peptides to assign the subsite 
specificity of the CHIP TPR domain at the four positions preceding the C-terminal Asp. 
This approach identified that in addition to the specificities mentioned above, the CHIP 
TPR could accommodate Leu at P5, preferred aromatic amino acids at P4, preferred 
bulky residues at P3 and preferred Pro at P2. When the optimal amino acids for each 
position were combined (CHIPOpt, Ac-LWWPD), the resulting peptide exhibited 
superior binding properties to the best know sequence (Hsp70, Ac-IEEVD). (Figure 
1.5C and Figure 1.5D) We also determined that we could use the specificity profile to 
accurately predict proteome derived interactors of CHIP. Given that caspases have a 
strong preference for P1 Asp residues, resulting in proteolytic product with C-terminal 
Asp, we developed an algorithm to predict CHIP binding sequences that would arise 
from caspase activity from among the nearly 500,000 Asp residues in the reference 
human proteome. These efforts led to the identification of over 2700 putative CHIP 
binding sequences likely to arise from caspase activity. We subsequently validated 
cleavage-site sequences in the microtubule associated protein tau (tau cleaved at Asp 
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421, tauD421) and active caspase-6 (caspase-6 cleaved at Asp179. caspase-6D179), both 
of which accumulate in Alzheimer’s disease. In vitro characterization of the interactions 
demonstrated that CHIP could rapidly ubiquitinate tauD421 in the absence of a 
chaperone. Additionally, binding to mature active caspase-6D179 mediated ubiquitin-
independent inhibition of caspase-6 activity akin to XIAP inhibition of caspases-3, -7 and 
-9. In total these data suggest a complex interplay between protein homeostasis 
networks and caspases mediated by the interactions of CHIP with chaperones as well 
as caspases, and caspase substrates. The inhibition of caspase-6D179 activity 
establishes a network architecture wherein the accumulation of CHIP binding 
sequences may potentiate cellular capase-6 via a feed-forward mechanism. (Figure 
1.5E)  
 It is interesting to consider the co-evolution of caspases and CHIP in the context 
of multicellularity. The TPR family of co-chaperones and the corresponding C-terminal 
interaction motif in Hsp70s and 90s are absent in prokaryotes but present in yeast. 
However, there is no yeast ortholog of CHIP. Yeast are also devoid of caspases or 
similar proteases with specificity for a P1 Asp that mediate programmed cell death. It is 
enticing to consider that CHIP and caspases evolved together in higher organisms to 
facilitate the transfer of information between caspases and protein homeostasis 
networks. Mutual antagonism between caspases and protein homeostasis has been 
established.69 It seems likely that the recruitment of proteostasis network components to 
caspase substrates (i.e. the association of CHIP function to caspase-6D179 and tauD421) 
and the concomitant disruption of critical PPIs in protein homeostasis networks (i.e. the 
disruption of CHIP:Hsp70/90 complexes by caspase substrates) will contribute to this 
	 16 
antagonism. Further work is necessary to ascertain the scope of CHIP activity as a 
caspase inhibitor, identify additional caspase substrates that bind to CHIP, and 
determine if this mechanism is common among the TPR co-chaperones. The 
development of chemical probes based on the CHIPOpt sequence will likely aid this 
endeavor and allow the probing of CHIP function in a manner inaccessible to genetic 
perturbations. 
 
7.  Implications of linking degradation to end binding in the proteome  
End-binding E3 ubiquitin ligase signaling is intimately intertwined with protease 
signaling wherein the activity of the E3 primes the emerging function of nascent termini. 
Additionally, some of these E3s (XIAP and CHIP) are capable of directly inhibiting the 
activity of proteases. While at this point these relationships seems to be enriched for the 
caspase family of proteases it is difficult to assess if this enrichment is representative or 
simply a biproduct of the robust phenotypes and available reagents for these proteases. 
Further work is essential to building a comprehensive understanding of how endo- and 
exo- proteolysis in the cell are linked to protein stability through end-binding E3s. These 
efforts will likely integrate modern proteomic methods for detecting cellular protein 
termini, activity-based protein profiling (ABPP) methods, as well as cellular and 
biochemical tools for assessing protease and end-binding E3 ligase specificity.70–75 
Notwithstanding any bias in our existing knowledge of these systems it is has become 
clear that protein termini, explicit or nascent, are a hotspot for regulation. The continued 
development of high-quality probes for individual components of these regulatory 
networks will be critical for elaborating useful models of these aspects of cell signaling. 
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However, these probes need not be limited to small molecules such as Smac mimetics 
or caspase-inhibitors. Drawing inspiration from anthrax LF one could imagine 
harnessing an exogenous protease to selectively alter the stability of proteins by 
changing the composition of their termini.76 In total it would seem that being mindful of 
the ends or proteins of interest is likely an important component of understanding 
biological function.  
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Figure 1.1. End binding E3 ubiquitin ligases regulate protease product stability to 
enable signaling. A, The balance of activity between PTM placing (E) and PTM 
removing (E*) enzymes controls the partitioning of function between modified and 
unmodified species for most PTMs. The irreversibility of proteolysis requires a different 
regulatory mechanism. B, End-binding E3 ubiquitin ligases can degrade the products of 
proteolysis and control proteolytic signal intensity and duration. C, E3 ubiquitin ligases 
provide specificity to the ubiquitin proteasome system by binding to degrons (yellow 
circles) and scaffolding substrate ubiquitination and subsequent delivery to the 
proteasome. D, When a protease (P) cleaves a substrate (S) that is subsequently 
recognized by and end-binding E3 ubiquitin ligase (E3), a functional interaction is 
created between protease and E3. These elements form a minimal signaling network. 
E, The strength of the functional link between a protease and an end-binding E3 is 
related to the overlap in the specificity between the protease active site and the terminal 
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recognition element (TRE) in the E3. This links S1-S4 subsites to C-terminal TREs and 
S1’-S4’ to N-terminal TREs. 
 
 
 
 
 
 
 
	 32 
Figure 1.2.  Specific determinants of N-end binding link protease and E3 function 
in signaling pathways. A, The X-ray crystal structure (PDB 3NY3, left panel) of the 
UBR N-end binding TRE from UBR2 (surface, grey) bound to a tetrapeptide (NH2-RIFS-
CO2H, sticks, yellow). Specificity for the N-terminal Arg is mediated by Asp150 and Asp 
153 (middle panel). UBR binds to the N-degron at the nascent N-terminus of a self-
cleavage product of USP1 after the N-terminal Gln is deamidated and argenylated. B, 
The X-ray crystal structure (PDB 3O2H, left panel) of the E-coli N-end binding TRE from 
ClpS (surface, grey) bound to a tetrapeptide (NH2-PGLW-CO2H, sticks, yellow). 
Specificity for the N-terminal Pro is mediated by coordination of the proline amine by 
Asn34, Asp35, and His66 (middle panel). A homologous domain in human UBR 1 and 2 
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is thought to direct the binding of Type II N-degrons. Generation of a Type II N-degron 
by Anthrax LF activity mediates NLRP1b inflammasome activation and cell death. C, 
The X-ray crystal structure (PDB 6CDC, left panel) of the GID4 N-end binding TRE from 
GID E3 ubiquitin ligase complex (surface, grey) bound to a tetrapeptide (NH2-PGLW-
CO2H, sticks, yellow). Specificity for the N-terminal Pro is mediated by coordination of 
the proline amine by Glu237(not shown) and backbone contacts with Gln132, Ser253, 
Ser278, Gln282 (middle panel). GID4 binds to the N-degron at the nascent N-terminus 
of a methionine aminopeptidase cleavage product of gluconeogenic enzymes including 
Fbp1 to mediate their rapid decay. 
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Figure 1.3. N-end binding is critical for the regulation of apoptosis. A, The X-ray 
crystal structure (PDB 1I3O) of the BIR2 domain of XIAP (grey, surface and cartoon) 
bound to caspase-3 dimer (yellow, surface and cartoon). BIR2 inhibition of caspase-3 
activity depends on its ability to occupy the active site (blue square), and bind the 
nascent N-terminal IBM motif generated by maturation of the enzyme (red square). B, 
The X-ray crystal structure (PDB 1NW9) of the BIR3 domain of XIAP (grey, cartoon) 
bound to caspase-9 monomer. BIR3 inhibition of caspase-9 depends on its ability to 
bind the nascent N-terminal IBM motif generated by maturation of the enzyme (red 
square) but not the active site (blue square). C, The X-ray crystal structure (PDB 1G37) 
of Smac dimer (Second mitochondrial activator of caspases, yellow, cartoon and 
surface) bound to BIR3 domain of XIAP (grey, cartoon and surface). Cleavage of Smac 
by PARL and release form the mitochondria allows the IBM motif generated by 
cleavage to sequester XIAP and relieve caspase inhibition. D, The N-terminal Ala in the 
IBM motif of Smac (NH2-AVPI) is specifically coordinated by Asp314 and Gln319. E, 
Complementary specificities of caspase-9, PARL, and XIAP establish a network 
architecture that encodes the signaling function of this system. 
 
 
 
 
Caspase-9 XIAP-BIR3Caspase-3 XIAP-BIR2
SMAC XIAP-BIR3
A1
V2
P3
I4
Trp3
Glu314
Thr3
Gly306
Gln319
Leu307
Trp310
Leu292
Lys297
Asp309
A B
C
D
E
IBM-Motif IBM-Motif
E3
P
S
Se
lf 
C
le
av
ag
e
XIAP
Caspase-9
S
P
PARL
Smac
IBM Motif
Trans-
m
em
brane 
cleavage
E
IBM
 
Mo
tif
EP P D T P FA TV L C V P IA
Caspase-9
	 35 
Figure 1.4. C-end binding adaptors to Cullin E3 ubiquitin ligases link degradation 
and non-prime protease specificity. A,The X-ray crystal structure (PDB 6DO5) the 
Cul2 adaptor KLHDC2 (grey, surface) bound to a C-terminal peptide derived form a self-
cleavage event in USP1 (NH2-IGLLGG-CO2H, yellow sticks, red square). B, The C-
terminal Gly is coordinated by Arg236, Arg241, and Ser269. C, Self-cleavage by USP1 
generates coincident N and C degrons with the potential to regulate USP1 function. 
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Figure 1.5.  C-end binding by the E3 ubiquitin ligase CHIP links caspases and 
protein homeostasis. A, Canonical CHIP (grey) function stems from an ability to bind 
to ubiquitin charged E2s (black) and cytosolic chaperones (i.e Hsp70s, red) to mediate 
ubiquitination of chaperone bound client (white). B, This function is rooted in the ability 
of CHIP (PDB 2Cl2, grey, cartoon and surface) to bind a conserved C-terminal motif 
(IEEVD-CO2H in Hsp70s and MEEVD-CO2H in Hsp90s, yellow, spheres) through its 
TPR domain (red square) and bring it into the proximity of E2 bound to the Ubox domain 
(PDB 20XQ, black, cartoon). C, Global profiling of the TPR domain specificity for 
proteinogenic amino acids expanded probable binders beyond canonical chaperone 
sequences. D, The C-terminal Asp of an optimized peptide bound to the CHIP TPR 
(PDB 6NS) is coordinated by Lys 30, Asn34, Asn65 and Lys95. E, Shared specificity 
with caspases mediates direct binding and inhibition of active capsase-6 (caspase-
6D179) and binding and ubiquitination of caspase-cleaved tau (tauD421). 
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Chapter 2 
 
Specificity for latent C-termini links the E3 ubiquitin ligase CHIP to 
caspases 
Matthew Ravalin, Panagiotis Theofilas, Koli Basu, Kwadwo A. Opoku-Nsiah, Victoria A. 
Assimon, Daniel Medina-Cleghorn, Yi-Fan Chen, Markus F. Bohn, Michelle Arkin, Lea 
T. Grinberg, Charles S. Craik and Jason E. Gestwicki. 
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Abstract. Protein-protein interactions between E3 ubiquitin ligases and protein termini 
shape the proteome. These interactions are sensitive to proteolysis, which alters the 
ensemble of cellular N- and C-termini. We have identified a mechanism wherein 
caspase activity reveals latent C-termini that are recognized by the E3 ubiquitin ligase 
CHIP. We expanded established CHIP specificity and identified hundreds of putative 
CHIP interactions arising from caspase activity. Subsequent validation confirmed that 
CHIP binds the latent C-termini at tauD421 and caspase-6D179 in vitro and in cells. CHIP 
binding to tauD421, but not tauFL, promotes its ubiquitination, while binding to caspase-
6D179 mediates ubiquitin-independent inhibition.  Given that caspase activity generates 
tauD421 in Alzheimer’s Disease (AD), these results suggest a concise model for CHIP 
regulation of tau homeostasis. Indeed, we find that a loss of CHIP expression in AD 
coincides with the accumulation of tauD421 and caspase-6D179. These results illustrate an 
unanticipated link between caspases and protein homeostasis. 
 
1. Introduction. An important subset of protein-protein interactions (PPIs) involve the 
recognition of a free amino (N) or carboxy (C) terminus by a binding partner 1–3. This 
type of PPI is sensitive to proteolysis, which irreversibly modifies the chemical 
composition of a protein’s terminus. Indeed, proteolysis can initiate binding events at 
protein termini and subsequently activate signaling cascades, including  protease-
activated receptor (PAR) signaling, apoptosis, and the unfolded protein response 4–6. 
Similar recognition events are important in maintenance of protein homeostasis (a.k.a. 
proteostasis). E3 ubiquitin ligases provide specificity to the ubiquitin proteasome system 
(UPS) by linking substrate-recognition and ubiquitination 7. A subset of E3 ubiquitin 
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ligase recognition domains are selective for protein termini; for example, the E3 
ubiquitin ligases of the N-end rule pathways (e.g. the UBR E3 ligases) recognize N-
termini bearing specific amino acids (N-degrons), prioritizing them for destruction via the 
UPS 8,9. In the N-end rule, proteolysis by methionine aminopeptidases plays a critical 
gatekeeping role by removing stabilizing N-terminal methionine residues to reveal UBR 
binding motifs 10,11. Analogous recognition of C-termini by adaptor proteins to Cullin-
RING E3 ubiquitin ligases has recently been shown to couple C-terminal recognition to 
turnover, perhaps through a protease-dependent pathway 12,13. Additionally, E3 ubiquitin 
ligases that recognize protein termini are central to the regulation of cell survival. 
Specifically, XIAP is a RING E3 ubiquitin ligase that inhibits the cystine proteases, 
caspase-3, -7 and -9 14. This inhibition deters the activation of apoptosis in a healthy 
cell. However, upon activation of apoptotic pathways, second mitochondrial activator of 
caspases (SMAC) is cleaved by the mitochondrial protease, PARL, allowing the free N-
terminus of SMAC to sequester the inhibitory domain in XIAP 15,16. Through these 
mechanisms, proteases enable recognition of latent termini to regulate critical cellular 
processes. 
Here, we report a protease-coupled recognition event wherein caspase activity 
reveals latent C-termini that are bound by carboxy-terminus of Hsp70-interacting protein 
(CHIP). CHIP is a homodimeric E3 ubiquitin ligase that contains a Ubox domain and a 
tetratricopeptide repeat (TPR) domain 17,18. The TPR domain was thought to be 
selective for the (I/M)EEVD motif present at the C-terminus of cytosolic members of the 
heat shock protein 70 (Hsp70) and 90 (Hsp90) families. These interactions favor the 
ubiquitination and turnover of both the chaperones and chaperone-bound substrates 
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19,20. Moreover, similar TPR domains are found in other Hsp70/Hsp90 co-chaperones 
such that competition for chaperone is thought to direct client fate 21,22. Here, we find 
that CHIP’s TPR domain has a broader specificity than previously appreciated, so that 
hundreds of latent C-termini may compete with Hsp70/Hsp90 in the context of caspase 
activation. We show that caspase cleavage of microtubule-associated protein tau 
(MAPT/tau) generates a high-affinity CHIP ligand. Strikingly, CHIP mediates in vitro 
poly-ubiquitination of cleaved tau (tauD421), but not full-length tau (tauFL), without the 
need for chaperone. In addition, we find that cleavage of caspase-6 during its 
maturation generates a strong CHIP recognition motif, which mediates potent ubiquitin-
independent inhibition of caspase-6D179. As both tau and caspase-6 cleavage are linked 
to AD, these findings suggested a possible feedback mechanism that links tau 
proteostasis and cell survival. In support of this model, we find that CHIP levels are 
decreased during progression of AD in patients, concomitant with an increase in 
cleaved tauD421 and active caspase-6D179. These results point to a much broader role for 
CHIP than its classical collaboration with Hsp70s/Hsp90s.  
 
2. CHIP TPR domain specificity extends beyond chaperones. Co-crystal structures 
have shown that Hsp70’s IEEVD motif binds to a groove in CHIP’s TPR domain, such 
that the two carboxylates of the C-terminal Asp form a bidentate interaction with CHIP’s 
carboxylate clamp formed by residues Lys30 and Lys95 (Figure 2.1A) 23. This 
interaction is common among TPR co-chaperones (Figure 2.1B). In addition, previous 
mutagenesis studies have identified the P5 (Ile in Hsp70s or Met in Hsp90s), P2 (Val), 
and P1 (Asp) as the critical positions for affinity and specificity 24. However, the global 
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binding specificity of CHIP’s TPR domain has not been explored. To achieve this, we 
designed a positional scanning synthetic combinatorial library (PSSCL) of acetylated 
five amino acid peptides 25,26. In this library, we fixed the C-terminal amino acid as an 
Asp and synthesized pools of peptides in which a second position was fixed, while each 
of the others contained a mixture of the twenty proteinogenic amino acids (see 
Methods). The resulting library consisted of eighty pools of eight thousand peptide 
sequences, each with two fixed positions (Figure 2.1C). To measure binding, we used 
two approaches. In the first, we determined the change in thermal stability (Tm) of CHIP 
in the presence of peptide pools by differential scanning fluorimetry (DSF) (Figure 
S2.1). We then confirmed these findings in fluorescence polarization (FP) experiments 
by measuring the capacity of each peptide pool to displace FP tracers derived from 
either the Hsc70 (HSPA8) or Hsp90⍺ (HSP90AA) sequences (Figure S2.2). These 
experiments reproduced the known determinants of chaperone binding to CHIP’s TPR 
domain and the results from the three biochemical platforms correlated well with each 
other (Figure 2.1D). In addition to the established specificities mentioned above, we 
identified unexpected preferences for Leu at P5, aromatic amino acids at P4, bulky 
residues at P3 and Pro at P2. Interestingly, we found that the best-known CHIP TPR 
binder (Hsp70’s IEEVD) was sub-optimal at all four positions queried. Using this 
information, we synthesized an optimized FP tracer (CHIPOpt; FITC-Ahx-LWWPD) and 
found that it bound CHIP with an apparent pKd of 7.8 ± 0.1 (Figure 2.1E). This affinity is 
significantly higher than that measured for tracers based on Hsp70s (FITC-Ahx-IEEVD; 
pKd of 6.8 ± 0.1) or Hsp90s (FITC-Ahx-MEEVD; pKd of 6.1 ± 0.1). An alanine scan of 
the CHIPOpt sequence in competitive FP experiments established that the positional 
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hierarchy of binding contributions was P2>P1>P4>P5>P3 based on perturbations to the 
pKi of the peptide (Figure 2.1F and Figure S2.3). This data suggests that the 
determinants of CHIP binding extend well beyond the established I/MEEVD motifs. 
 
3. CHIPOpt engages distinct interactions with CHIP. To better understand the 
molecular determinants of CHIP specificity, we solved X-ray crystal structures of the 
human CHIP TPR domain bound to acetylated 5mer peptides corresponding to the 
Hsp70 sequence (Ac-IEEVD, PDB 6EFK) and CHIPOpt (Ac-LWWPD, PDB 6NSV) at 
1.5Å and 1.3Å respectively (Figure 2.2A, Figure S2.4A B,C, Table S2.1). It is worth 
noting that the CHIPOpt structure included density at the crystallographic interface of 
the two peptide-bound TPR domains in the asymmetric unit, which is not present in the 
Hsp70 peptide-bound structure (Figure S2.4C). This density appeared as a linear chain 
that wrapped around the epsilon nitrogen of Lys72 in each TPR domain. Given this 
typical host-guest orientation and the presence of polyethylene glycol (PEG) in the 
crystallization conditions we modeled the densities as two PEG-6 molecules. 
As mentioned above, CHIP belongs to a family of proteins that use TPR domains 
to bind Hsp70 and Hsp90 C-termini. However, CHIP’s TPR domain is unique among 
these proteins because it contains a discrete hydrophobic pocket formed by an extra 
turn in helix 6 and an elongated linker between helices 6 and 7, which orient residues 
Phe98, Phe131 and Ile135 around P5 in the bound peptides (Figure 2.2B, Fig S2.4D). 
This arrangement favors a kinked conformation of bound peptides, which contrasts with 
the linear arrangement of similar peptides in the TPR domain of HOP (Figure S2.4E) 27. 
Consistent with this idea, we found that both Hsp70-derived peptide and CHIPOpt 
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peptide had the expected kinked binding mode. A closer examination of the relative 
orientation of these peptides helped explain why CHIPOpt was a superior ligand. To 
further that effort, we also performed a computational analysis of the bound peptide in 
Rosetta 28. Briefly, using the Hsp70-bound structure as a template, we computationally 
estimated perturbations to the free energy of folding (##Gfold) for the protein-peptide 
complex upon saturation mutagenesis of the peptide. By this analysis, the amino acids 
that provided the greatest increases in affinity, such as P4 aromatics and P2 proline, 
agreed between the experimental results and computational predictions (Table S2.2). 
Moreover, direct comparison of the P2 position in the Hsp70 and CHIPOpt crystal 
structures revealed a +19º perturbation to the ɸ dihedral angle, suggesting that the 
conformational rigidity of the proline may enhance favorable contacts elsewhere in the 
ligand and reduce the entropic cost of binding (Figure 2.2C, P2-V & P2-P). We also 
observed that the P4 Trp of CHIPOpt packs on a hydrophobic shelf formed by F98 and 
F99, which is not engaged by the corresponding P4 Glu in the Hsp70-bound structure. 
Given that F99 bridges the P4 and P5 binding sites, it is likely that the P4 aromatic also 
further reinforces the kinked peptide binding mode (Figure 2.2C, P4-E & P4-W) Another 
striking difference between the Hsp70 and CHIPOpt structures is an apparent shift in 
hydrogen bonding at the peptide N-terminus. In our Hsp70 structure and all published 
CHIP-peptide co-crystal structures, D134 in the TPR domain forms a hydrogen bond 
with the amide nitrogen of the P5 amino acid (Figure 2.2D, grey). However, in the 
CHIPOpt structure, this hydrogen bond does not form. Instead, the amide oxygen of the 
acetyl group forms a hydrogen bond with K95 (Figure 2.2D, yellow). This shift seems 
to support an exaggerated kink in the CHIPOpt conformation. In total, the structural and 
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computational data suggests that the enhanced affinity of CHIPOpt likely arises from 
optimized interactions at P2, P4 and the N-terminus. Together, these results indicate 
that previously unknown, high-affinity interactions with CHIP exist within the human 
proteome. 
 
4. Proteome-wide prediction of CHIP interactions. We next used the expanded 
specificity of the CHIP TPR domain to generate an algorithm for predicting peptide 
sequences that would bind to CHIP (termed CHIPScore). Briefly, PSSCL data from the 
DSF dataset were normalized to the peptide pool with the highest signal (P2 Pro) 
(Figure S2.5A). Then, each value for an amino acid at a given position was summed so 
that a CHIPScore is equal to the sum of the normalized values for P5, P4, P3 and P2 
(Figure 2.3A). To validate the scoring function, we compared the CHIPScore to the 
measured pKi values of the CHIPOpt peptide and its variants as well as Hsp70 and 
Hsp90 sequences. In this analysis, CHIPScore correlated well with the experimental pKi 
values (R2 = 0.86) (Figure 2.3B). Then, we used CHIPScore to search for binders in the 
human proteome. First, of the 20,246 protein sequences in the reference proteome, we 
found that 973 have a C-terminal Asp residue. Among these, only cytosolic Hsp70s and 
Hsp90s terminate in the canonical (I/M)EEVD motif. However, using CHIPScore, we 
found an additional eight predicted interactions whose: (i) score exceeded Hsp90 
(MEEVD CHIPScore = 1.79) and (ii) were expressed in the cytosol or nucleus (Figure 
2.3C, Figure S2.5B, Table S2.3). Two proteins on this list (NADE and TXLNG) had 
previously been identified in proteomic studies as potential CHIP binders (Taipale et 
al.), supporting the predictive power of the scoring function. 
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This finding suggested that only a small number of possible interactions could be 
identified in the intact C-terminome. However, taking inspiration from the central role of 
proteolysis in revealing N-termini, we expanded our search space to include latent C-
termini that are only unmasked by the activity of proteases. Here, “latent” is used to 
describe a new C-terminus that can be produced by proteolytic activity. Of the human 
proteases with well-annotated specificity, the caspase family of cysteine proteases was 
of particular interest because they exhibit a strong preference for Asp at the P1 position, 
such that their activity yields a new C-terminus ending in this residue 29,30. Moreover, 
extensive experimental and bioinformatic efforts have been previously undertaken to 
identify and predict caspase substrates. Specifically, 1651 unique P1 Asp caspase 
cleavage sites have been experimentally validated by N-terminomics 31. When we 
searched this dataset with CHIPScore, we identified 84 C-termini that are likely to bind 
better than Hsp90 to CHIP (Figure S2.5C, Table S2.4). Encouraged by these results, 
we expanded the search to include a proteome-wide dataset of predicted caspase 
cleavage sites, which were generated from a support vector machine (SVM) scoring 
function 32. To set a threshold SVM score, we compared the distribution of 493,321 
proteome-derived SVM scores to the 1,651 experimentally validated caspase cleavage 
sites and set a cutoff that would include 75% of the validated sites (SVM=-0.464) 
(Figure S2.5D, E). This process yielded 2,757 candidates with latent C-termini that are 
predicted to be high affinity ligands for CHIP (Figure 2.3D, Figure S2.5F, Table S2.5). 
We anticipate that this list includes many new PPIs between CHIP and caspase 
substrates, perhaps providing a rich source of regulatory interactions.    
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To validate a subset of this data, we curated the lists of predicted candidates 
from the explicit and latent C-terminome datasets. This process directed our attention to 
tau (cleaved at Asp421; tauD421) and an auto-proteolytic activation site of the inter-
domain linker in the caspase-6 zymogen (cleaved at Asp179; caspase-6D179) 33. These 
sites were of interest because tauD421 and caspase-6D179 have both been shown to 
accumulate in the brains of AD patients 34–36. However, the mechanism underlying the 
accumulation of these specific fragments has been unclear. Moreover, CHIP had 
previously been linked to the clearance of tauD421in cellular and animal models 37–39. 
Thus, we considered a model in which CHIP might serve as a key regulator of both tau 
homeostasis and caspase-6 activity through recognition of latent C-termini in each 
protein. Before proceeding, we confirmed that peptides based on tauD421 and caspase-
6D179 indeed bound (pIC50 values 7.1 ± 0.1 and 5.9 ± 0.1 respectively) to CHIP’s TPR 
domain using competitive FP experiments (Figure 2.3E and Figure S2.5G).  
 
5. Caspase cleavage of tau at D421 recruits CHIP. In healthy neurons, tau binds to 
microtubules through its microtubule binding repeats (MBRs) 40. However, in AD, tau is 
known to dissociate from microtubules to form neurofibrillary tangles (NFTs) 41. In the 
NFTs, tau is often post-translationally modified, including by proteolytic cleavage 42. 
Specifically, tau contains a number of validated caspase cleavage sites that accumulate 
during disease progression (Figure 2.4A) 43. Our CHIPScore predictions suggested that 
the D421 site, in particular, would create a high affinity CHIP-binding site. To explore 
this idea, we first determined whether CHIP selectively bound the tauD421 epitope over 
others. Using competitive FP experiments, we screened peptides corresponding to the 
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reported caspase cleavage sites, establishing that only the peptide from tauD421 
interacts with CHIP (Figure S2.6A). To validate binding in the context of a full-length 
protein, we expressed and purified the 0N4R splice isoform of tau (tauFL) that is 
expressed in adult neurons, as well as the corresponding tauD421 truncation. We found 
that only tauD421, and not tauFL, could bind to CHIP (pIC50 of 6.2 ± 0.03); (Figure 2.4B). 
This specificity was confirmed using synthetic FP tracers corresponding to the ten 
amino acids at the C-terminus of tauFL and tauD421 (Figure 2.6B). Independent analyses 
by DSF corroborated the selectivity for cleaved tau (Fig S2.6C,D) in the context of full-
length protein. Multiple caspases have been implicated in tau processing during AD. To 
determine which ones might produce the tauD421 epitope, we created a corresponding 
10 amino acid fluorogenic substrate (see Methods) and monitored its cleavage in the 
presence of a commercially-available panel of active caspase enzymes. This 
experiment showed that caspase-3 had the most specific activity for the site in the 
conditions tested, although caspases-1, -6 and -7 also had activity (Figure S2.6E). 
Indeed, the addition of active caspase-3 (at t = 0) was able to convert tauFL into a CHIP-
binding species in a kinetic FP assay (Figure S2.6F). Next, we wondered whether the 
direct interaction of CHIP with tauD421 might promote ubiquitination in vitro. These 
studies showed that tauD421, but not tauFL, was rapidly (~3 min) poly-ubiquitinated by 
CHIP in the presence of an E2/E1/Ub/ATP mixture. Use of CHIPK30A, a mutation in the 
carboxylate clamp, significantly reduced the ubiquitination of tauD421 (Figure 2.4C), 
confirming that the interaction required binding to the TPR domain. This robust 
ubiquitination was also observed for tauFL processed by caspase-3 in situ to generate 
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tauD421 (Figure S2.6G). Thus, when tauD421 is produced by caspase activity, it directly 
binds to the CHIP TPR domain and the protein can be poly-ubiquitinated. 
To validate the CHIP-tauD421 interaction in a cellular context, we generated stable 
cell lines expressing a doxycycline inducible GFP-0N4R construct terminating in either 
the tauFL sequence, the tauD421 truncation, or tauD421A. Live-cell fluorescence microscopy 
confirmed that all three proteins were properly associated with cytoskeletal structures 
consistent with microtubules (Figure 2.4D). Also, microtubule fractionation showed that 
each of them was associated with the insoluble pool (Figure 2.4E). In the absence of 
tau expression, endogenous CHIP was present in the soluble fraction in all three cell 
lines (lanes 1,3,5). This localization was unperturbed by the expression of either tauFL or 
tauD421A (lanes 2,6). However, induced expression of GFP-tauD421 (lane 4) dramatically 
partitions CHIP to the insoluble, microtubule fraction. These results suggest that CHIP 
tightly and specifically associates with tauD421 in a cellular context. 
 
6. CHIP specifically inhibits mature caspase-6D179.Active caspase-3, -7 and -9 are 
inhibited by the E3 ubiquitin ligase XIAP; however, an equivalent endogenous inhibitor 
for caspase-6 is not known 44. Caspase-6 undergoes a maturation process similar to 
caspase-3 and caspase-7 wherein the cleavage of the pro-domain and inter-subunit 
linker yield the mature, fully activated enzyme. The fully mature enzyme bears the 
predicted CHIP binding site, caspase-6D179, at the C-terminus of the large subunit 
(Figure 2.5A). To understand whether CHIP might act as an endogenous caspase-6 
inhibitor, we expressed and purified active enzyme as two polypeptide chains with the 
large subunit terminating at Asp179 and the small subunit terminating with a 6His tag. 
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Competition binding experiments confirmed that active caspase-6D179 binds to CHIP 
(pIC50 = 6.6 ± 0.08) (Figure 2.5B).  The specificity of this interaction to C-terminal 
recognition was confirmed using biolayer interferometry (BLI) and comparing 
immobilized CHIP to CHIPK30A (Figure S2.7A). We predicted that CHIP would poly-
ubiquitinate caspase-6D179 in vitro, as was observed for tauD421. However, similar 
experiments showed that active caspase-6D179 was not robustly ubiquitinated under 
these conditions (Figure S2.7B). However, we found that CHIP acted as an inhibitor of 
caspase-6D179 substrate hydrolysis. Specifically, we used proteolysis of a fluorogenic 
peptide substrate (Ac-VEID-AMC) to monitor caspase-6D179 activity in the presence of 
CHIP. A kinetic analysis demonstrated potent inhibition of substrate turnover and a 
mode of action consistent with competitive inhibition (an increase in Km) (Figure 2.5C). 
No significant inhibition was detected with the addition of a CHIPK30A (Figure S2.7C). 
Thus, CHIP inhibits caspase-6 function, but through a mechanism distinct from XIAP 
regulation of other caspases. 
To determine whether CHIP binds mature caspase-6 in a cellular context, we first 
generated active caspase-6 in Jurkat cells by treating them with staurosporine (1μM) for 
two hours. Control and staurosporine treated cell lysates were supplemented with 
recombinant biotinylated CHIP or biotinylated CHIPK30A. Bound proteins were enriched 
on streptavidin coated magnetic beads, washed, and eluted. We used antibodies 
specific for caspase-6D179 (e.g. active) or caspase-6FL (e.g. inactive) to perform Western 
blot analyses on cell lysates and eluates from pulldowns. We found that caspase-6FL 
was depleted upon treatment with staurosporine and that neither CHIP or CHIPK30A 
were capable of pulling it down (Figure 2.5D, left panel). Conversely, active caspase-
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6D179 was specifically enriched by pulled-down with CHIP but not CHIPK30A (Figure 
2.5D, right panel). These experiments demonstrate that the CHIP-caspase-6 
interaction is dependent on the maturation of the enzyme and integrity of the CHIP TPR 
carboxylate clamp.  
 
7. CHIP loss coincides with neoepitope accumulation in AD. These results suggest 
a molecular mechanism to explain why tauD421 and active caspase-6D179 accumulate in 
neurons during AD progression. Specifically, we hypothesized that CHIP levels or 
function might be diminished during disease progression, contributing to increases in 
active caspase-6D179 and failure to clear tauD421 (Figure 2.6A). To test this idea, we 
developed a multiplexed fluorescent immunostaining method to interrogate the levels of 
tauD421, active caspase-6D179, and CHIP in the hippocampus of fixed human tissue from 
donors with AD pathology in early, middle and late stages of the disease (Braak I, III, 
and VI, respectively). Briefly, Braak staging characterizes the spread of neurofibrillary 
tangles across cortical regions and is widely used to stage AD pathology 45. Consistent 
with the literature, we found that hippocampal Braak VI tissue exhibited the most 
significant accumulation of tauD421 and active caspase-6D179. In addition, we observed a 
striking loss in CHIP expression in Braak III and VI (Figure 2.6B). Analysis of RNAseq 
data from the Allen Brain Atlas revealed that CHIP mRNA does not significantly change 
as a function of Braak stage, ApoE status, or age (Figure S.8A, B and C) 46, suggesting 
that the observed loss of CHIP at Braak III and VI occurs post transcriptionally. 
Together, these findings support a model in which loss of CHIP expression allows 
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accumulation of tauD421 and potentiates the activity of caspase-6, contributing to the 
accumulation of both C-termini in AD. 
 
8. Discussion. Proteostasis mechanisms that act on protein termini, such as the N-End 
Rule pathways, are fundamentally important in sculpting the proteome. The work 
described here identifies a C-terminal recognition process that recruits CHIP to sites of 
caspase cleavage. By determining the specificity of CHIP’s TPR domain, we identified 
~2,700 latent C-termini that are predicted to be regulated by this protein. Further work is 
needed to probe the scope and specific roles of these interactions; however, as an 
initial proof-of-principle, we were drawn to the observation that both tauD421 and 
caspase-6D179 were putative CHIP ligands. These proteins had been linked to AD and to 
each other, yet it was not clear how or if they might be co-regulated and what this might 
mean for the disease. Indeed, we found that CHIP binds both tauD421 and caspase-
6D179, directing the ubiquitination of tauD421 and inhibiting caspase activity in a ubiquitin-
independent way. Both interactions were of high affinity and could be readily observed 
in cell-based models. Linking these observations together, histopathology studies in AD 
brains suggested that loss of CHIP could be a contributor to the accumulation of these 
latent C-termini in advanced disease. Thus, these findings may generate new ideas for 
the treatment of AD. Given the clinical failures in this therapeutic area, new targets and 
mechanisms are of utmost importance.   
It is worth noting that the identification of CHIP as an endogenous inhibitor of 
caspase-6 fits well into existing paradigms of caspase signaling. Caspase activity in a 
cell is limited at multiple levels 47. However, among the broader caspase family, the 
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regulation of caspase-6 is less understood. Like the other executioner caspases, 
caspase-6 is capable of auto-activation and exists as a constitutive homodimer 48. 
However caspase-6 is insensitive to XIAP and it has a unique attributes that separate it 
from the other caspases 49,50. Thus, our finding that CHIP inhibits caspase-6 suggests a 
novel mechanism of caspase regulation and fills a gap in the regulatory framework of 
these important signaling proteases.  
Finally, CHIP was previously thought to act primarily (or even exclusively) as a co-
chaperone for cytosolic Hsp70/Hsp90. Our work shows that, in some cases CHIP 
circumvents the requirement for chaperone and binds directly to protein targets. We 
found that few C-termini within explicit open reading frames (ORFs) are likely to 
compete with the Hsp70/Hsp90 interaction, but that caspase cleavage created a large 
number of possible binding events at latent C-termini. We used minimal affinity cut-off 
values based on the CHIP-Hsp90 interaction, such that the predicted contacts might be 
expected to compete with the canonical chaperone-dependent roles. However, given 
the abundance of chaperones in cells, more work will be needed to understand which of 
these putative contacts displace chaperones from CHIP. An additional complexity is the 
roles of the other TPR co-chaperones, such as FKBP51 and PPP5C, which also 
converge on the shared (I/M)EEVD motifs. It seems likely that caspase activity could 
broadly remodel chaperone and non-chaperone PPIs, creating new opportunities to 
rapidly and post-translationally regulate critical signaling nodes in cells. 
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10. Methods 
Protein Purification 
Unless otherwise stated all proteins were produced in E. coli BL21(DE3) and stored at -
80° C. 
CHIP and CHIP K30A (human, His-tagged) were expressed from a pET151 construct 
with a N-terminal TEV- cleavable 6His Tag. E. coli were grown in terrific broth (TB) at 37 
°C, induced with 500 μM IPTG in log phase, cooled to 18° C and grown overnight. Cells 
were harvested, resuspended in binding buffer (50 mM Tris pH 8.0, 10 mM imidazole, 
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and 500 mM NaCl) supplemented with protease inhibitors, sonicated, clarified, and 
supernatant was applied to Ni-NTA His-Bind Resin (Novagen). Resin was washed with 
binding buffer and His wash buffer (50 mM Tris pH 8.0, 30 mM imidazole, and 300 mM 
NaCl). Protein was eluted from the resin with His elution buffer (50 mM Tris pH 8.0, 300 
mM imidazole, and 300 mM NaCl). N-terminal His tag was removed by overnight dialysis 
with TEV protease at 4° C. Digested material was applied to His-Bind resin to remove 
cleaved His tag, undigested material, and TEV protease. Protein was further purified by 
size exclusion chromatography (Superdex 200) in 50 mM HEPES pH 7.4, 10 mM NaCl.  
 
CHIP TPR Domain (human, AA 22-154, His-tagged) was expressed from a pMCSG7 
construct with an N-terminal TEV-cleavable 6His tag. E. coli were grown in TB at 37 °C, 
induced with 1mM IPTG in log phase, cooled to 24° C and grown overnight. Ni-NTA 
purification and tag removal were conducted as for FL CHIP. Protein was further purified 
on a Mono S cation exchange column and stored in 10 mM Tris pH 8.0, 150 mM NaCl, 
and 2 mM DTT. 
 
0N4R tauFL and 0N4R tauD421 (human) were expressed from a pET28 construct. E. coli 
were grown in TB at 37° C. NaCl (500 mM) and betaine (10 mM) were added to media 
prior to log phase induction with 200 µM IPTG for 3.5 h at 30 °C. Cells were harvested, 
lysed by microfluidizer, and lysate was boiled for 20 min. Clarified lysate was dialyzed 
into 20 mM MES, pH 6.8, 50 mM NaCl, 1 mM EGTA, 1 mM MgCl, 2 mM DTT, 0.1 mM 
PMSF and purified by cation exchange. 
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Caspase-6D179(human, His-tag) Large subunit (AA 31–179) and small subunit (AA 194–
293, 6XHis) in pET24b (+) and pET23b (+) vectors were co-transformed into Rosetta BL2 
(DE3) cells. E. coli were grown in 2XYT medium at 37° C, and induced in log phase with 
0.2 mM IPTG for 20 h at 16 °C. Cells were harvested, resuspended in 100 mM Tris, pH 
8.0, 100 mM NaCl, and lysed by microfluidizer. Supernatant was loaded to Ni-NTA His-
Bind Resin for 1 h at 4° C. Resin was washed 2X with 100 mM Tris, pH 8.0, 100 mM 
NaCl, and 1X with 100 mM Tris, pH 8.0, 100 mM NaCl 40 mM imidazole. Protein was 
eluted with 50 mL 100 mM Tris, pH 8.0, 100 mM NaCl 200 mM imidazole. Further 
purification was achieved by anion exchange over a linear gradient of 0 – 1 M NaCl in 20 
mM Tris pH 8.0. 
 
UbcH5c (human) was expressed from a pET2 construct. E. coli were grown in TB at 37° 
C and induced in log phase with 500 μM IPTG overnight at 16 °C. Cells were harvested, 
washed with PBS, and resuspended in 30 mM MES pH 6.0, 1 mM DTT, 1 μg/mL 
Leupeptin, 1 μg/mL Aprotinin and 1 mM PSMF, sonicated and clarified. Purification was 
achieved by cation exchange chromatography (SP Sepharose) followed by size exclusion 
chromatography (Superdex 200) in 50mM Tris, 50 mM KCl, pH 8.0. 
 
Ube1 (human, His-tagged) was expressed from a pET21d construct. E. coli were grown 
in TB at 37° C and induced in log phase with 500 μM IPTG overnight at 16 °C. Cells were 
harvested, washed with PBS, and resuspended in  50 mM Tris, 150 mM NaCl, 1 mM 
EDTA-NaOH, pH 8.0, 1 mM DTT, 0.1% (w/v) Triton X-100, 1 mM PSMF, 1 protease 
inhibitor tablet and sonicated. The soluble fraction was loaded onto Ni-NTA His-Bind 
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Resin for 2 h at 4 °C, washed with 50 mM sodium phosphate pH 8.0 150 mM NaCl and 
eluted in 50 mM sodium phosphate pH 8.0, 150 mM NaCl, 100 mM imidazole. Further 
purification was achieved by anion exchange chromatography in 10 mM Tris pH 8.0, 1 
mM EDTA, 1 mM DTT and size exclusion chromatography (Superdex 200) in 20 mM Tris 
pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT. 
 
Ubiquitin (human) was expressed from a pET15 construct. E. coli were grown in TB at 
37° C and induced in log phase with 500 μM IPTG overnight at 16 °C. Cells were 
harvested, washed with PBS, resuspended in Lysis buffer (50 mM Tris, 1mM EDTA pH 
7.6 + 0.05% Tween-20) and sonicated. The soluble fraction was dialyzed twice into 3.5 L 
50 mM sodium acetate pH 4.5.  Dialyzed sample was pelleted by centrifugation at 18,000 
RPM for 20 min. Supernatant was loaded onto a cation exchange column (SP Sepharose) 
and eluted in 50 mM sodium phosphate pH 4.5 and NaCl. Fractions containing ubiquitin 
were purified further by SEC (Superdex 75) in 50 mM Tris pH 8.0, 50 mM KCl. 
 
Protein modification with maleimide-biotin or maleimide-FAM 
Tau and CHIP were dialyzed into 25 mM HEPES pH 7.4 50 mM KCl, 1 mM TCEP and 
labeled with 1.1 eq of maleimide-biotin or maleimide-FAM for 1 h at room temperature. 
Caspase-6 was labeled with 2 eq maleimide-FAM overnight at 4° C in purification buffer 
supplemented with 1 mM TCEP. Excess reagent was removed by iterative dilution and 
concentration. 
 
Peptide Synthesis  
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Peptides were synthesized by Fmoc solid phase peptide synthesis on a Syro II peptide 
synthesizer (Biotage) at ambient temperature and atmosphere on a 12.5 μmol scale using 
pre-loaded Wang resin. Coupling reactions were conducted with 4.9 eq of HCTU (O-(1H-
6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro- phosphate), 5 eq of 
Fmoc-AA-OH and 20 eq of N-methylmorpholine (NMM) in 500 uL of N,N dimethyl 
formamide (DMF). Reactions were run for 8 min while shaking. Each position was double 
coupled. Fmoc deprotection was conducted with 500 uL 40% 4-methypiperadine in DMF 
for 3 minutes, followed by 500 μL 20% 4-methypiperadine in DMF for 10 minutes, and six 
washes with 500 μL of DMF for three minutes. Acetylation was achieved by reaction with 
20 eq acetic anhydride and 20 eq NMM in 500 μL DMF for 1 h while shaking. Peptides 
were cleaved with 500 μL of cleavage solution (95% Trifluoroacetic acid 2.5% Water 2.5% 
Triisoprpylsilane) while shaking for 1 h.  Crudes were precipitated in 10 mL cold 1:1 diethyl 
ether : hexanes. Peptide crudes were solubilized in a 1:1:1 mixture DMSO: water: 
acetonitrile and purified by HPLC on a Agilent Pursuit 5 C18 column (5 mm bead size, 
150 mm x 21.2 mm) using an Agilent PrepStar 218 series preparative HPLC. The mobile 
phase consisted of A: Water 0.1% Trifluoroacetic acid and B: Acetonitrile 0.1% 
Trifluoroacetic acetic acid. Solvent was removed under reduced atmosphere and 10 mM 
DMSO stocks were made based on the gross peptide mass. Purity was confirmed by 
LC/MS. Stocks were stored at -20 °C. Fluorescein isothiocyanate (FITC) was added to 
FP tracers by reacting 1.7 eq of FITC and 20 eq of NMM in 500 uL of DMF for while 
shaking for 1 h. FITC capping reactions were run twice. The quenched fluorogenic peptide 
corresponding to the tauD421 site (NH2-K(MCA)IDMVD/SPQLAK(DNP)-COOH) was 
synthesized as above where fluorophore (7-Methoxycoumarin-4-acetic acid (MCA)) and 
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the quencher (2,4-dinitrophenyl (DNP)) are linked to the epsilon nitrogen of a lysine. 
Peptide was synthesized using Wang resin pre-loaded with Fmoc-Lys(DNP)-OH 
(Millipore). Fmoc-Lys(MCA)-OH coupling reactions were conducted with 1.7 eq monomer 
and HCTU. 
 
The PSSCL library was synthesized using standard coupling conditions outlined above. 
“Mixed” positions in the library were coupled with an equimolar mixture of all twenty 
proteinogenic Fmoc protected amino acid monomers. Pools were cleaved and used 
without further purification. Molecular weights were estimated by using 110 Da (the 
average MW of a natural amino acid) for mixed positions. 
 
DSF 
PSSCL screens were conducted in a 96-well qRT-PCR plate on a Strategene Mx3005P-
rtPCR. Each well contained 10 μL 10 μM CHIP in in 25 mM HEPES pH 7.4 50 mM KCl 1 
mM TCEP, 10 μL of 200 μM PSSCL pool in the same buffer + 0.2% CHAPS + 2% DMSO, 
and 5 μL 25X Sypro Orange dye. Fluorescence intensity readings were taken over 70 
cycles where reactions were heated to desired temp and then cooled to 25° C before 
reading. Temperature was increased at a rate of 1° C per cycle. Fluorescence Intensity 
data was normalized and truncated at 55° C to fit to a Boltzmann Sigmoid in Graphpad 
Prism 7.0. 
Y=Bottom+((Top-Bottom)/(1+exp(Tm-T/Slope)) (1) 
Binding to CHIP was assessed by the change in Tm. 
DTm = DTPOOL-DTDMSO (2) 
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Tau DSF was conducted as above with 10 μL of 10 μM (1eq) tau in lieu of the peptide 
library. 
 
FP Binding Assay 
FP assays were run in 18 μL in a Corning black 384 well round bottom low volume plate 
and read on a BioTek H4 multimode plate reader at 21° C. 
 
PSSCL screens were performed by measuring displacement of CHIP tracers 
corresponding to the Hsc70 or Hsp90a sequences (FAM-Ahx-SSGPTIEEVD and FAM-
Ahx-DDTSRMEEVD). 2X Protein-tracer complexes (20 nM Tracer +2X EC85 CHIP) were 
prepared in 25 mM HEPES pH 7.4 50 mM KCl 1 mM TCEP. 2X (200 μM) PSSCL pool 
was prepared in the same buffer + .2% CHAPS + 2% DMSO. Each solution was added 
to the well and incubated for 15 min. DPolarization (mP) was calculated relative to DMSO 
control. Final concentration of CHIP was 1.58 μM for Hsc70 and 3.48 μM for Hsp90⍺. 
 
Saturation binding assays with 1 nM FITC-CHIPOpt (FITC-Ahx-LWWPD), FITC-Hsp70 
(FITC-Ahx-IEEVD), and FITC-Hsp90 (FITC-Ahx-MEEVD) were run in a final buffer 
composition of 25 mM HEPES pH 7.4, 50 mM KCl, .01% Triton X-100 and 1% DMSO. 
Raw polarization (mP) data were normalized and plotted relative to log10[CHIP]M.  Data 
was fit to the model for log(agonist) vs response (variable slope) in Graphpad Prism 7.0. 
Kd was extrapolated from EC50. Tau tracer saturation binding was identical except that 
0.1% CHAPS was substituted for .01% Triton X-100 and tracer concentration was 20 nM. 
Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X) *HillSlope)) (3) 
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Competition binding assays A 2X stock of CHIP+Tracer was made in HEPES pH 7.4, 
50 mM KCl so that the final concentration of protein would be ECX and tracer would be 1 
nM. 2X peptide stock was prepared in 25 mM HEPES pH 7.4 50 mM KCl .02% Triton X-
100 and 2% DMSO. Raw polarization (mP) data were plotted relative to log10[Peptide]M.  
Data was fit to the model for log(antagonist) vs response (variable slope) in Graphpad 
Prism 7.0. 
 
Y=100/(1+10^((LogIC50-X)*HillSlope))) (4) 
 
Ki was calculated form EC50 51. 
Ki=[I]50/([L]50/Kd+[P]0/Kd+1) (5) 
 
Kinetic FP A 2X stock of CHIP+Tracer (1000 nM CHIP 20 μM FAM-Ahx-SSGPTIEEVD) 
was prepared in 25 mM HEPES pH 7.4 50mM KCl 1 mM TCEP, 0.1% CHAPS. A 2X stock 
of tauFL or tauD421 (20 μM) was prepared in the same buffer. 9 μL of each 2X stock were 
added to the wells in triplicate. An initial FP reading was recorded. 2 μL of active caspase-
3 (10X or 50nM) in the same assay buffer and added to each well. FP readings were 
taken every 46 s for 20 min. A well with no tau was included to account for effects of 
caspase on CHIP binding to tracer. 
 
Competition binding with FL Tau and Caspase-6 were run identically to peptide 
competition binding experiments with the Hsp70 tracer (FITC-Ahx-IEEVD) but in 50 mM 
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HEPES pH 7.5, 25mM MgSO4, 0.5 mM EGTA, 5 mM reduced glutathione, and .01% 
Triton X100. Tracer was used at a final concentration of 20 nM. 
X-Ray Crystallography 
The protein solution was prepared by mixing a 1:1 molar ratio of human CHIP-TPR, at 7 
mg/ml, and the 5mer 70 or CHIPOpt peptide in protein buffer (10 mM Tris-HCl pH 8.0, 
150 mM NaCl and 2 mM DTT), and incubated on ice for 30 min. Crystals of the complex 
were grown at room temperature by hanging-drop by mixing 100 nL of the protein solution 
with 100 μL of the crystallization condition (Hsp70: 0.4 M CaCl2, 0.1 M HEPES (pH 7.5), 
25% PEG 4K) CHIPOpt: 0.05M CaCl2, 0.1 HEPES (pH 7.0), 28% PEG 4K, 0.01M CoCl2)  
by TTPLabtech Mosquito Nanoliter Dropsetter. Crystals appear within 24 h and were 
harvested ~ 1 week after setup by flash-freezing in liquid nitrogen using a cryogenic 
solution of 50% MPD in the crystallization condition. Data were collected at Lawrence 
Berkeley National Laboratory Advanced Light Source beamline 8.3.1. Diffraction images 
were processed using Xia2 with the Dials pipeline 52. Automatic molecular replacement 
was performed using the online Balbes tool 53. The resulting structure models were 
refined over multiple rounds of restrained refinement and isotropic B-factor minimization 
with Phenix 54. For 6EFK Ramachandran favored=98.5%, allowed=1.5%, outliers=0%. 
For 6NSV Ramachandran favored=98.46%, allowed=1.54%, outliers=0%.   
 
Rosetta DDG calculations 
The energetics of particular mutations were assessed computationally using 
ddg_monomer from the Rosetta suite using the solved structure of CHIP TPR bound to 
Ac-IEEVD peptide as starting model. Structures of starting model and mutants underwent 
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three rounds of energy minimization. Fifty iterations of the DDG optimization process were 
performed and the model with the lowest overall energy was used for analysis. 
 
Protease Activity Assays 
Caspase screening was conducted with a panel of commercially available active 
caspase -1, -2, -3, -6, -7, -8, -9 and -10 (Enzo Life Sciences, ALK-850-243-KI01). 1 unit 
of enzyme was added to 10 μM of fluorogenic substrate corresponding to the tauD421 
cleavage site in 25 mM HEPES pH 7.4 50 mM KCl 0.1% CHAPS 1 mM TCEP.  
Fluorescence intensity was monitored as a function of time. Enzymes were compared 
based on the initial velocity of the reaction. 
 
Caspase 6 kinetic assays The activity of a final enzyme concentration of 10 nM was 
monitored using a fluorogenic substrate (Ac-VEID-AMC).  To each well was added a 4X 
stock of caspase-6D179 and a 4X stock of CHIP in 50 mM HEPES pH 7.5, 25 mM MgSO4, 
0.5 mM EGTA, 5 mM reduced glutathione, and 0.01% Triton X100. This mixture was 
incubated at ambient temperature for 10 min. Substrate was added immediately prior to 
reading as a 2X stock in 50 mM HEPES pH 7.5, 25 mM MgSO4, 0.5 mM EGTA, 5 mM 
reduced glutathione, and 0.01% Triton X100 +2% DMSO. Activity was monitored at 30 s 
intervals for 10min. V0 was calculated from data collected in the interval between 30 s and 
360 s in arbitrary units (RFU/s). 
 
Ubiquitination Assays 
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Four 4X stocks were prepared: (A) Ube1 + UbcH5c (400 nM Ube1 and 4 μM UbcH5c), 
(B) Ubiquitin (1 mM Ub), (C) ATP + MgCl2 (10 mM ATP and 10 mM MgCl2), and (D) CHIP 
+ substrate (4 μM CHIP and 4 μM FAM-MAPT or FAM-caspase-6) in 50 mM Tris, 50 mM 
KCl, pH 8.0. Ubiquitination reactions were set up by adding 27.5 μL of each 4X stock, in 
order from A to D, for a final volume of 110 μL (100 nM Ube1, 1 μMUbcH5c, 250 μM 
ubiquitin, 2.5 mM ATP, 2.5 mM MgCl2, 1 μM CHIP, 1 μM FAM-substrate). Reactions 
incubated at room temperature, quenching 10 μL aliquots in 5 μL 3X SDS-PAGE running 
buffer after the appropriate incubation period. Gel was imaged at Alexa488 channel on 
Biorad Imager.   
 
Biolayer Interferometry 
A qualitative analysis of the selective interaction between CHIP and caspase-6D179 was 
conducted using biolayer interferometry (BLI) on an Octet Red 384well system (ForteBio). 
Biotinylated CHIP or CHIP K30A were loaded onto a BLI sensor coated with streptavidin.  
Association was observed by immersing loaded tips into solutions of caspase-6D179 at 
varying concentrations in 50 mM HEPES pH 7.5, 25mM MgSO4, 0.5 mM EGTA, 5 mM 
reduced glutathione, and 1% BSA for 240 s. Dissociation was observed by transferring 
the tip of a well with the same buffer and no caspase-6 for 450 s. Relative binding was 
assessed qualitatively. 
 
SDS PAGE Gels 
All SDS PAGE was run on a precast 15will 4-15% gel (Biorad) for 33 min at 200V  
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Western Blotting 
Transfers were conducted on nitrocellulose membranes using a Trans-Blot Turbo 
Transfer system (Bio-Rad). Membranes were blocked with Odyssey TBS blocking buffer 
(Licor) for 1h at room temperature. Primary antibodies were diluted 1:2000 in blocking 
buffer and incubated overnight at 4C. Membranes were washed 5x3min with TBST and 
probed with secondary for 1h at room temperature. Secondaries were washed 5x3min 
with TBST and imaged on a Licor Fc imaging system. 
 
Imaging 
Cells were seeded in a clear bottom, TC treated 96 well plate at 10K cells/well in 100μL 
complete growth medium and allowed to adhere overnight. Cells were induced with 10 
μg/mL Doxycycline for 72h. Nuclei were counter stained with 1 μg/mL Hoechst 33342 in 
complete growth media for 30 min before imaging. Live-cell images were taken at 40X 
magnification on a GE InCell 6000. 
 
Microtubule Pulldowns  
Flp-In T-Rx 293 cell lines expressing GFP-0N4R tau constructs were generated, 
propagated, and stored according to the manufacturer’s instructions 
(https://www.thermofisher.com/order/catalog/product/R78007). 150K cells were seeded 
in a 6-well plate in 3 mL complete growth medium (DMEM, 10% FBS, 1% 
Penicillin/Streptomycin), allowed to adhere for 12h, and induced with 10 μg/mL 
Doxycycline for 72h. Media was removed and cells were washed with DPBS. Cell 
membranes were lysed with 90 μL of a microtubule-stabilizing lysis buffer (20 mM MOPS 
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pH 6.8, 50 mM NaCL, .5% NP-40, 2 mM EGTA, 1 mM MgCl2, 2 mM TCEP, 2 μg/mL 
paclitaxel, 2 mM GTP, 250 unit/mL benzonase) and rocked gently for 3 min. Soluble lysate 
was removed gently with a cut pipette tip. The well was rinsed gently with 45 μL of lysis 
buffer and the soluble fraction and centrifuged at 15K RPM at room temp. 50 μL of was 
diluted in 3X SDS-PAGE loading buffer. 200 μL of 1X SDS-PAGE loading buffer was 
added to the well to solubilize the microtubule fraction. Samples were boiled and 15 μL 
loaded for Western Blot analysis. Membranes were probed with mouse ⍺GFP (Santa 
Cruz), mouse ⍺Tubulin (Santa Cruz), and Rabbit ⍺CHIP (Abcam). Blots were developed 
using Licor secondary antibodies (Goat-⍺Rabbit 680RD and Goat-⍺mouse 800CW). 
 
Biotin-CHIP Pulldowns 
Jurkat cells were cultured according to ATCC (RPMI-1640, 10% FBS, 1% 
Penicillin/Streptomycin). For pull-down experiments cells were seeded at 500K/mL in 
complete growth media and treated with either 1 μM Staurosporine (from a 1000X DMSO 
stock) or DMSO alone for 2h. Cells were harvested by centrifugation and washed with 
DPBS. Washed cell pellets were flash frozen. Cells pellets were thawed and lysed at 
room temp for 5 min while shaking in 10 μL of M-PER (Thermo-Fischer Scientific) per 
million cells. 50 μL (5 million cells) of lysate was diluted with 150 μL of TBS pH 8.0. 
Biotinylated CHIP (WT or K30) was added to the diluted lysate so that the final 
concentration of CHIP was 1 μM and the mixture was allowed to incubate for 1h. After 
incubation Biotinylated CHIP was enriched by incubation with 100 μL of streptavidin 
coated magnetic bead slurry (MagneSphere, Promega) for 1h at room temperature.  
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Beads were washed 3x with TBS and eluted in 50 μL of 1X loading buffer. 15 μL of eluate 
was for Western Blot analysis with Licor secondary antibody (Goat ⍺Rabbit 800CW). 
 
Brain Immunofluorescence 
The de-identified post mortem tissues were sourced from the Brain Bank of the Brazilian 
Brain Aging Study Group and the Neurodegenerative Disease Brain Bank at UCSF as 
previously described (https://memory.ucsf.edu/neurodegenerative-disease-brain-bank) 
55. AD was categorized according to the Braak staging system and CERAD 
neuropathology criteria. All cases represented sporadic AD and included Braak 1 (early 
AD), Braak 3 (mid-AD), and Braak 6 (late AD). Blocks of the entorhinal cortex-
hippocampus were embedded in paraffin and cut in serial sections. To visualize the 
interaction of different markers and their overlapping positivity, the sections were stained 
with multiplex immunofluorescence (IF). Sections were autoclaved in citrate buffer 
retrieval solution at 121 °C. Primary antibodies (aCasp6 from Aviva Scientific, CHIP from 
Sigma Aldrich and TauC3 from Life Technologies; all 1:200) were incubated overnight, 
followed by species-specific secondary antibodies for 1 h. Neuronal cell bodies were 
labeled with Neurotrace 435/455 for 30 min (1:50; Life Tech), a fluorescent Nissl stain. 
Sections were visualized with a 20x objective (Plan Apo N.A. 0.75, Nikon, Japan) using 
a Nikon 6D high throughput wide field epifluorescence microscope (Nikon, Tokyo, Japan) 
at the UCSF Nikon Imaging Center. 
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Figure. 2.1. CHIP function is rooted in the recognition of C-termini. A, A composite 
structural model depicting how the CHIP homodimer (grey surface/cartoon) positions 
the E2 ubiquitin conjugating enzyme UBCH5 (black cartoon) so that the chaperone tail 
is 58Å away from the activated ubiquitin thioester (yellow spheres) (PDB: 2C2L and 
2OXQ). The critical motif for chaperone binding to CHIP spans the last five amino acids 
(P5,4,3,2,1, yellow) of Hsp70s and Hsp90s (PDB: 3Q49). B, Lines represent 
experimentally validated interactions between cytosolic Hsp70 (red) or Hsp90 (blue) 
chaperones with TPR co-chaperones (black circles). CHIP (yellow) is the only E3 
ubiquitin ligase amongst these TPR co-chaperones. C, The terminal sequences of 
Hsp70s (red) and 90s (blue) bind to CHIP’s TPR domain. Positions P5, P2, and P1 
(yellow) are critical for binding. A PSSCL library was designed to sample amino acid 
diversity at P5, P4, P3 and P2. D, Each peptide pool was analyzed by DSF and two 
competitive fluorescence polarization (FP) assays, yielding D(Tm) and D(mP) values. 
Pearson’s r was used to compare the data sets to one another. These experiments 
indicated that affinity is not optimized in the natural peptides (IEEVD or MEEVD). E, A 
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saturation FP experiment with tracers corresponding to the optimized sequence 
“CHIPOpt” (FITC-Ahx-LWWPD, black), Hsp70 (FITC-Ahx-IEEVD, red), and Hsp90 
(FITC-Ahx-MEEVD, blue). Normalized polarization is plotted for individual replicate 
samples (n=3) in a representative experiment. Reported pKd is a mean of pKd values 
from independent experiments (n=3) with error reported as SEM. F, Competition binding 
FP experiments with an alanine scanning library of CHIPOpt. pKi values calculated from 
independent experiments (n=3) are plotted individually (open circles). Bars represent 
mean pKi. Error is plotted as SEM. 
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Figure. 2.2. Structural basis for CHIP TPR domain specificity. A, X-ray crystal 
structures of Hsp70 peptide (PDB ID 6EFK) or CHIPOpt peptide (PDB ID 6NSV) bound 
to CHIP’s TPR domain were solved at 1.5 and 1.3 Å respectively. B, The overall binding 
mode is conserved between Hsp70 and CHIPOpt peptides. C, At the P2 position the 
proline in CHIPOpt fixes the ɸ at -67.5º vs -86.4 for the P2 valine in Hsp70. The P4 
tryptophan in CHIPOpt occupies a hydrophobic shelf formed by F98, F99, and L68. D, A 
kinked backbone orientation supports hydrogen bonding between the acetyl oxygen and 
K95 in the carboxylate clamp by CHIPOpt (yellow) rather than the acetyl nitrogen and 
D134 in Hsp70 (grey). 
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Figure. 2.3. Proteome-wide prediction of CHIP TPR interactions with C-termini. A, 
A model of CHIP TPR specificity where the contribution of P5-P2 is denoted by the size 
of the circle (where Area µ DpKi for a given Ala variant relative to CHIPOpt). CHIPScore 
is defined as the normalized sum of thermal shifts from the PSSCL DSF dataset for a 
given peptide sequence. B, Correlation (R2) between CHIPScore and experimental pKi 
(n=3, see Figure 1f) for the CHIPOpt alanine scanning library, as well as Hsp70 (red) 
and Hsp90 (blue) peptides. The degree of correlation was determined by linear 
regression. The fit and the 95% confidence interval are represented by the dotted and 
solid lines, respectively. C, The application of CHIPScore to the reference proteome 
identified proteins (black) with C-termini that are predicted to bind CHIP. Proteins that 
are predicted to be outside the cytosol or nucleus (dashed) would not be expected to 
interact with CHIP.  Proteins previously identified as putative CHIP interaction partners 
are shown by arrows (Taipale et al.). D, Proteome wide prediction of latent CHIP 
binding C-termini likely to be unmasked by caspase activity, based on CHIPScore (x-
axis) and caspase scoring (y-axis). Caspase scoring was based on a support vector 
machine (SVM) prediction function for caspase cleavage (Barkan et al 
https://modbase.compbio.ucsf.edu/peptide//). Hits (yellow) fall above a CHIPScore 
threshold of 1.79 (the value for Hsp90’s MEEVD) and SVM threshold of (-0.464) (see 
methods and Supplementary Fig 5). E, The location of predicted CHIP interaction sites 
on caspase-6D179 and tauD421. pIC50 values calculated from independent experiments 
(n=3) are plotted individually (open circles). Bars represent mean pIC50. Error is plotted 
as SEM. 
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Figure. 2.4. TauD421 specifically recruits CHIP A, Schematic of how tau dissociates 
from microtubules and forms high-order aggregates during the progression of AD. 
Multiple caspase cleavages sites in tau, including D421, have been reported to 
accumulate in AD. B, In a competition binding FP experiment, tauD421 but not tauFL 
displaces tracer bound to CHIP. Polarization (mP) is plotted for individual replicate 
samples (n=3) in a representative experiment. Reported pIC50 is mean of three 
independent experiments with error reported as SEM. C, In vitro ubiquitination 
experiment with CHIP(E3), UBCH5c(E2), Ubiquitin, and ATP demonstrates selective 
ubiquitination of tauD421 but not tauFL by CHIP. Use of CHIPK30A diminishes 
ubiquitination. Results are representative of three independent experiments.  D, TauFL, 
tauD421, or tauD421A were stably expressed with an N-terminal GFP tag under the control 
of a Tet repressor ((TetO2)2) in TREx HEK293 cells. Representative live cell image 
shows GFP-tau (green, false color) associated with cytoskeletal structures.  Scale bar is 
30 μm. Nuclei are labeled with Hoechst (blue, false color). E, A microtubule fractionation 
assay for all three GFP-tau cell lines +/- 10 μg doxycycline for 72h after seeding. 
Probing with anti-GFP reveals that GFP-tau is in the microtubule-bound fraction (bottom 
panel). A low MW GFP positive band (*) was detected in the soluble fraction (top panel). 
Tubulin is distributed between the soluble and microtubule-bound fractions. CHIP is 
predominantly in the soluble fraction but is re-partitioned to the microtubule-bound 
fraction when tauD421 is expressed. Results are representative of three independent 
experiments. Uncropped blots in Supplementary Fig 9.  
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Figure. 2.5 CHIP specifically binds and inhibits mature caspase-6. A, Caspase-6 is 
a constitutive homodimer that undergoes iterative proteolytic cleavages at three distinct 
sites (yellow circles) during maturation to yield a CHIP binding site (D179) at the C-
terminus of the large subunit  B, A competition binding FP experiment, caspase-6D179 
displaces tracer bound to CHIP. Polarization (mP) is plotted for individual replicate 
samples (n=3) in a representative experiment. pIC50 is reported as a mean of three 
independent experiments with error reported as SEM. C, In a fluorogenic substrate 
cleavage assay, caspase-6D179 is competitively inhibited by increasing concentrations of 
CHIP. The reciprocal of initial velocity (1/V0) is plotted relative to 1/[S] for individual 
replicate samples (n=3) in a given experiment. Results are representative of three 
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independent experiments. D, Western blots show that caspase-6 zymogen (top panel, 
C-6FL) does not pull down with recombinant biotinylated CHIPWT or CHIPK30A from Jurkat 
cell lysate. Caspase-6D179 is specifically generated in cells treated with staurosporin (1 
µM) for 2h and is enriched in eluates from CHIPWT but not CHIPK30A (bottom panel, C-
6D179). Results are representative of three independent experiments. Uncropped blots in 
Supplementary Figure 2.9. 
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Fig. 2.6 CHIP interactions at latent C-termini suggest a role in the progression of 
AD A, An integrated model of expanded CHIP functions including chaperone- and 
caspase-coupled ubiquitination of tau (MAPTD421), as well as inhibition of caspase-6. B, 
Immunofluorescence signals and high-magnification insets of caspase-6D179 (green), 
tauD421 (red) and CHIP (yellow) positive neurons (blue Neurotrace/Nissl) in the 
hippocampal area CA1 of human brains from early (Braak I), middle (Braak III) and late 
(Braak VI) stages of AD. Scale bars: 50 μm; insets: 10 μm. Qualitative analysis for this 
study was conducted based on trends within the three samples presented in this figure. 
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Table S2.1  
Structural data collection and refinement statistics (molecular replacement) 	 	 Hsp70(6EFK)	 CHIPOpt(6NSV)	
Data	collection	 	 	Space	group	 P	21	21	21	 P	2	21	21	Cell	dimensions  	 	 					a,	b,	c	(Å) 46.71	70.34	77.07	 46.22	71.92	77.79	
    a, b, g 	(°)		 90	90	90	 90	90	90	Resolution	(Å)	 39.95-1.50	(1.55-1.50)*	 39.73	-1.31		(1.35		-	1.31)*	
Rsym	or	Rmerge	 0.1539	(1.749)	 0.03455	(0.6336)	
I	/	sI	 9.42	(1.55)	 11.09	(1.24)	Completeness	(%)	 96.64	(86.34)	 94.66	(89.46)	Redundancy	 11.5	(7.1)	 2.0	(2.0)	
	 	 	
Refinement	 	 	Resolution	(Å)	 1.50	 1.31	No.	reflections	 39996	 60397	
Rwork	/	Rfree	 0.2107/0.2442	 0.2145/0.2427	No.	atoms	 2534	 2447					Protein	 2209	 2172					Ligand/ion	 7	 41					Water	 318	 234	
B-factors	 19.33	 25.09					Protein	 17.73	 24.22					Ligand/ion	 14.78	 32.86					Water	 30.54	 31.73	R.m.s.	deviations	 	 					Bond	lengths	(Å)	 0.008	 0.01					Bond	angles	(°)	 1.15	 1.05	*Data	was	collected	from	1	xtals	for	both	structures	
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Table S2.2 
CHIP-TPR with 5mer ddg_monomer values for the parent sequence (red) and predictions 
at P4 and P2 (yellow). 		
 																						
AA P5 P4 P3 P2 P1
A -3.575 0.362 -0.674 1.048 -1.33
C -2.28 -0.08 -0.98 1.616 -0.89
D -0.298 2.674 1.33 7.444 0.019
E -0.555 -0.021 0 6.386 -0.559
F -6.41 -1.779 -1.836 7.365 0.534
G -4.823 1.268 0.521 2.745 -1.259
H -4.647 -0.481 -0.865 3.863 -0.162
I 0.13 -0.546 -0.488 3.271 -1.891
K 3.832 0.349 0.096 13.283 -0.943
L -3.204 -1.997 -0.893 5.378 -0.931
M -3.78 -0.871 0.129 1.629 -2.13
N -3.216 0.07 -0.457 2.618 -0.499
P -2.216 2.406 10.33 -1.726 5.08
Q -1.279 -0.273 0.18 2.506 -1.013
R 9.239 1.929 -1.398 17.138 -0.056
S -3.866 1.237 -1.117 2.174 -0.955
T -2.486 -0.422 -0.919 0.586 -1.567
V -2.932 -0.675 -0.667 0 -0.632
W -0.372 -2.24 -1.72 5.149 -1.183
Y -1.393 -1.151 -2.376 8.253 -0.079
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Table S2.3 
CHIPScore hits from the explicit C-terminome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Entry Sequence CHIPScore Entry name
Q86WH2 VWKPD 2.44 RASF3_HUMAN
Q8IW40 LYQVD 2.36 CC103_HUMAN
P02747 LLFPD 2.30 C1QC_HUMAN
Q7Z5L3 LLYPD 2.19 C1QL2_HUMAN
Q5VXU3 IFRPD 2.19 CHIC1_HUMAN
Q9UKJ5 IFRPD 2.19 CHIC2_HUMAN
Q8N3L3 LEGVD 2.12 TXLNB_HUMAN
Q9H5X1 VLEPD 2.09 FA96A_HUMAN
Q6IA69 LDGVD 2.07 NADE_HUMAN
P17066 IEEVD 2.05 HSP76_HUMAN
P0DMV9 IEEVD 2.05 HS71B_HUMAN
P54652 IEEVD 2.05 HSP72_HUMAN
P34931 IEEVD 2.05 HS71L_HUMAN
P0DMV8 IEEVD 2.05 HS71A_HUMAN
P11142 IEEVD 2.05 HSP7C_HUMAN
Q8NFB2 IEMPD 2.03 T185A_HUMAN
Q05D32 LLPPD 2.03 CTSL2_HUMAN
P07510 LPSPD 2.00 ACHG_HUMAN
Q9H7F4 IDMPD 1.99 T185B_HUMAN
Q86Z23 IIYPD 1.96 C1QL4_HUMAN
P0C671 VESPD 1.93 CF222_HUMAN
P21854 FRFPD 1.89 CD72_HUMAN
Q9NUQ3 IESVD 1.86 TXLNG_HUMAN
Q6PL45 YYLPD 1.85 BRID5_HUMAN
Q58FF7 MEEVD 1.79 H90B3_HUMAN
P07900 MEEVD 1.79 HS90A_HUMAN
P08238 MEEVD 1.79 HS90B_HUMAN
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Table S2.4 
CHIPScore and SVM Scores for hits identified in the Degrabase. Entries with no SVM 
(denoted #N/A) Score were not present in the SVM database. 
 
Entry 5mer P1Site SVMScore CHIPScore Entry Name
Q15477 LEEPD 800 -0.46 2.37 SKIV2_HUMAN
Q9H9J4 LEEPD 764 1.27 2.37 UBP42_HUMAN
Q8WYQ5 LDEPD 396 2.64 2.32 DGCR8_HUMAN
Q00613 LYAPD 256 0.26 2.32 HSF1_HUMAN
A7XYQ1 LLTPD 298 -0.96 2.25 SOBP_HUMAN
Q9UER7 LDDPD 219 0.95 2.24 DAXX_HUMAN
O95347 LDEVD 1116 2.66 2.19 SMC2_HUMAN
Q92619 LVDPD 662 1.27 2.18 HMHA1_HUMAN
P00558 LGRPD 68 0.65 2.18 PGK1_HUMAN
Q8TD55 LDVPD 179 1.94 2.17 PKHO2_HUMAN
O15042 LEDVD 712 1.20 2.15 SR140_HUMAN
Q7L2H7 ILEPD 77 -1.25 2.15 EIF3M_HUMAN
O43164 LDQVD 86 1.76 2.14 PJA2_HUMAN
Q9Y5V3 ISEPD 222 3.38 2.13 MAGD1_HUMAN
Q96SB3 LVEVD 551 2.05 2.13 NEB2_HUMAN
Q13601 LTVPD 38 1.00 2.13 KRR1_HUMAN
Q2TAL8 LLTVD 290 -0.15 2.12 QRIC1_HUMAN
Q14980 VEEPD 1829 1.06 2.12 NUMA1_HUMAN
O14818 VFSPD 13 -0.35 2.11 PSA7_HUMAN
Q12888 LSDVD 211 0.66 2.11 TP53B_HUMAN
Q9Y2K2 IVEPD 383 1.23 2.08 SIK3_HUMAN
Q96HN2 LVSPD 109 0.57 2.07 SAHH3_HUMAN
Q9UL15 LFEID 54 1.06 2.07 BAG5_HUMAN
Q9UKA4 LTCVD 1081 0.95 2.06 AKA11_HUMAN
Q09666 IDTPD 3718 -0.34 2.05 AHNK_HUMAN
O60486 LDVVD 1008 1.99 2.04 PLXC1_HUMAN
Q9NR50 LVGVD 355 -0.07 2.01 EI2BG_HUMAN
Q9P2N5 TYEPD 487 1.59 2.01 RBM27_HUMAN
Q66K74 LDRVD 286 0.81 2.01 MAP1S_HUMAN
P31350 LSLVD 29 -0.88 2.00 RIR2_HUMAN
Q9P2M7 LSSVD 173 -0.27 2.00 CING_HUMAN
Q7Z3T8 LSSVD 107 1.54 2.00 ZFY16_HUMAN
P27797 IKDPD 212 0.28 1.99 CALR_HUMAN
Q15181 VDDPD 165 0.91 1.99 IPYR_HUMAN
P24666 NWRVD 43 -0.42 1.99 PPAC_HUMAN
P09651 VEEVD 69 0.35 1.99 ROA1_HUMAN
Q09666 ISMPD 1583 -1.09 1.99 AHNK_HUMAN
Q09666 ISMPD 2711 -2.12 1.99 AHNK_HUMAN
Q09666 IDVPD 865 -0.70 1.98 AHNK_HUMAN
Q09666 IDVPD 2882 -0.38 1.98 AHNK_HUMAN
Q9Y6Q9 GSWPD 1012 0.22 1.98 NCOA3_HUMAN
Q9H6T3 IDVPD 451 1.00 1.98 RPAP3_HUMAN
P49411 LDAVD 244 0.57 1.97 EFTU_HUMAN
Q09666 VEVPD 919 -1.26 1.96 AHNK_HUMAN
Q01804 VGVPD 9 0.27 1.95 OTUD4_HUMAN
P08134 IDSPD 90 0.26 1.94 RHOC_HUMAN
Q9H1B7 LNHVD 132 1.32 1.94 I2BPL_HUMAN
Q3KQV9 VCQVD 299 0.99 1.93 UAP1L_HUMAN
P13639 CFGPD 655 -0.72 1.93 EF2_HUMAN
P16989 VTGPD 161 0.65 1.92 YBOX3_HUMAN
Q15650 FTEPD 122 0.13 1.91 TRIP4_HUMAN
Q09666 IDAPD 737 -0.95 1.91 AHNK_HUMAN
Q13023 LNAVD 1387 1.15 1.91 AKAP6_HUMAN
P13010 LNAVD 455 -0.77 1.91 XRCC5_HUMAN
P61758 VEDVD 35 -0.45 1.90 PFD3_HUMAN
Q8NCN2 VGDVD 135 #N/A 1.89 ZBT34_HUMAN
Q9Y608 VIIPD 531 1.04 1.89 LRRF2_HUMAN
Q06547 VTMPD 303 0.26 1.89 GABP1_HUMAN
O43719 GGEPD 39 0.35 1.88 HTSF1_HUMAN
Q8NDI1 FDDPD 274 1.06 1.87 EHBP1_HUMAN
P55735 INTVD 9 -0.74 1.86 SEC13_HUMAN
Q9NQV6 IESVD 115 0.87 1.86 PRD10_HUMAN
P30260 VISPD 243 -0.42 1.85 CDC27_HUMAN
Q15545 VSTVD 100 0.28 1.85 TAF7_HUMAN
Q96IZ0 EEEPD 131 2.22 1.85 PAWR_HUMAN
Q09666 VSAPD 5580 -0.86 1.85 AHNK_HUMAN
P53621 ITGVD 188 0.60 1.85 COPA_HUMAN
P26639 VTLPD 89 -0.91 1.85 SYTC_HUMAN
P06396 GSEPD 639 0.85 1.84 GELS_HUMAN
P23634 LDEID 1080 1.00 1.84 AT2B4_HUMAN
P55265 VVRPD 214 1.68 1.83 DSRAD_HUMAN
P55265 VVRPD 263 0.44 1.83 DSRAD_HUMAN
Q15056 FDEVD 93 1.71 1.82 IF4H_HUMAN
Q14566 VSGVD 274 0.95 1.82 MCM6_HUMAN
Q9Y6W5 VENVD 242 0.85 1.82 WASF2_HUMAN
Q53EP0 WESPD 791 0.56 1.81 FND3B_HUMAN
Q15003 GDFPD 366 2.29 1.81 CND2_HUMAN
P55347 CSEPD 36 0.34 1.81 PKNX1_HUMAN
Q9H0V1 FCSPD 426 -0.29 1.81 TM168_HUMAN
Q86WB0 GTEPD 449 1.05 1.81 NIPA_HUMAN
Q8IWI9 IHAVD 680 0.40 1.80 MGAP_HUMAN
Q13432 ESEPD 44 1.10 1.80 U119A_HUMAN
Q8NCJ5 VMMVD 214 -0.70 1.79 SPRY3_HUMAN
Q13435 VARPD 473 #N/A 1.79 SF3B2_HUMAN
Entry 5mer P1Site SVMScore CHIPScore Entry Name
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Table S2.5 
CHIPScore and SVM Scores for hits identified in the Proteome. 
Supplementary Table 5 is available free of charge at the following link https://www.nature.com/articles/s41589-019-0322-6#Sec29	
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Figure S2.1. DSF PSSCL Screen of CHIP TPR Specificity Normalized DSF data (y= 
Normalized Fluorescence intensity, x=° C) in the range of 30 °C to 50 °C. DTm is values 
were calculated from the difference of calculated Tm for CHIP with 100 µM peptide pool 
(red) vs a DMSO control (black). Optimal residues at each position are highlighted in 
yellow boxes. 
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Figure S2.2 Competition Fluorescence Polarization PSSCL Screen. Competition FP 
assays for CHIP binding to tracers corresponding to a, Hsc70 (HspA8) and b, Hsp90a 
(Hsp90AA). The observed change in polarization (DmP) is plotted relative to the dynamic 
range of the assay (dotted line). Each peptide pool was incubated with tracer bound to 
CHIP at 100 µM and the tracer concentration was set to EC85. Delta mP values are plotted 
for individual replicate samples (open circles, n=4). Means are represented as bars with 
error plotted as SD. 
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Figure S2.3. Competition binding of acetylated 5mer peptides. Representative 
competition binding curves for acetylated 5mer peptides CHIPOpt (Ac-LWWPD), 
CHIPOpt Ala Scan (P1-P5), Hsp70 peptide (Ac-IEEVD) and Hsp90 peptide (Ac-MEEVD). 
CHIPOpt, CHIPOpt P5A, and CHIPOpt P3A competitions were conducted with CHIP 
bound to a FITC-CHIPOpt tracer at EC85. Polarization (mP) values for individual replicate 
samples (n=4) are plotted. CHIPOpt P4A, CHIPOpt P2A, CHIPOpt P1A, Hsp90 and 
Hsp70 competitions were conducted with CHIP bound to a FITC-Hsp70 tracer at EC50. 
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Polarization (mP) values for individual replicate samples (n=3) are plotted. Results are 
representative of three independent experiments. 
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Figure S2.4. Structural studies of peptide-bound CHIP-TPR. A, Crystal structure of 
the human CHIP TPR domain bound to Hsp70 (6EFK) and B, CHIPOpt (6NSV). Peptide 
is presented in sticks and CHIP-TPR shown as surface. C, A density unique to the 
crystallographic interface in the CHIPOpt structure (6NSV) was modeled as two PEG6 
molecules based on a host-guest interaction with K72 in both of the TPR protomers in the 
asymmetric unit. D, An overlay of ten structures of TPR co-chaperone TPR domains (AIP 
(4AIF), CHIP (3Q49), FKBP4 (1KT0), PPP5 (1A17), RPAP3_TPR1 (3CGV), 
RPAP3_TPR2 (3CGW), SGTA (2VYI), STIP1_TPR1 (1ELW) STIP1_TPR2 (1ELR), and 
UNC45A (2DBA), highlights the unique loop in CHIP (red, ribbon) that forms the P5 
binding site for the Ile in the Hsp70 peptide (yellow, sticks). E, A comparison of the peptide 
binding modes of an Hsp70-derived peptide (PTIEEVD-CO2-) bound to HOP TPR1 (grey, 
1ELW) and CHIP (yellow) highlights the kink in the CHIP bound peptide relative to the 
extended peptide conformation when peptide is bound by HOP TPR1.  
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Figure S2.5. CHIPScore of the C-terminome, degradome, and proteome. A, 
“CHIPScore” was based on the sum of normalized thermal shift values calculated from 
the PSSCL DSF data set, where CHIPScore = P5+P4+P3+P2. For a given amino acid 
sequence B, CHIPScores for the native C-terminome identified 27 C-termini with a 
CHIPScore that exceeded that of HSP90. C, CHIPScores for C-termini generated by 
experimentally validated caspase cleavage sites from the Degrabase 
(https://wellslab.ucsf.edu/degrabase/) identified 84 C-termini with scores that exceeded 
Hsp90. D, To identify latent C-termini with aspartates likely to be unmasked by caspase 
activity, we used a dataset generated by a support vector machine (SVM) scoring function 
designated to weigh the likelihood of cleavage at a given aspartate in the proteome 
(https://modbase.compbio.ucsf.edu/peptide//). Comparison of SVM scores for the 
proteome (black) and experimentally validated cleavage sites from the Degrabase (grey) 
showed a significant enrichment of higher SVM scores in the true positives. A SVM 
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threshold capturing 75% (horizontal line) of validated cleavages (SVM=-.464, vertical line) 
was set to identify probable cleavage sites. E, Scoring of the Degradome dataset with 
CHIPScore and SVM scoring confirmed that a majority of CHIPScore hits fell above the 
SVM threshold (yellow). F, CHIPScore and SVM scoring of 493,321 aspartic acids in the 
proteome yielded 2,757 hits including tauD421 and caspase-6D179 (inset, yellow). G, 
Competition binding curves for acetylated 5mer peptides TauD421 (Ac-IDMVD) and 
caspase-6D179. Polarization (mP) values for individual replicate samples (n=3) are plotted. 
Competitions were conducted with CHIP bound to a FITC-Hsp70 tracer at EC50. Results 
are representative of three independent experiments. 
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Figure S2.6.  Caspase cleavage at tauD421 directs binding of and ubiquitination by 
CHIP. A, A screen of known caspase-generated latent C-termini (grey bars) from tau in 
a competition FP binding assay at 100 µM showed that only tauD421 is capable of 
binding the CHIP TPR domain. Hsp70 (red) and Hsp90 (blue) are included as positive 
controls. Delta mP values are plotted for individual replicate samples in a given 
experiment (open circles, n=4). Means are represented as bars with error plotted as SD 
B, Saturation FP experiment with tracers corresponding to the explicit C-terminus (grey) 
and the latent C-terminus tauD421 (black) confirmed selectivity. Polarization is plotted for 
individual replicate samples (n=3) in a given experiment. Results are representative of 
three independent experiments. C, DSF confirmed that CHIP (black) was not stabilized 
by the addition of FL 0N4R tau (light grey) but was significantly stabilized (>5 ºC) by 
tauD421 (dark grey) Normalized fluorescence intensity is plotted for individual replicate 
samples (n=3). D, Calculated Tm for Fig S6c based on a fit of the data to a Boltzmann 
sigmoidal. Error is plotted as the SEM. E, A screen of a commercial panel of 
recombinant active caspases determined that caspase-3 was the most efficient at 
cleaving an internally quenched fluorogenic substrate corresponding to the tauD421 site. 
Initial velocity is plotted for individual replicate samples (n=3) in the experiment F, 
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Addition of 5 nM caspase-3 (at t=0, dotted line) to a competition binding assay 
containing tauFL (black) induces the time dependent generation of tauD421 and the 
displacement of bound FP tracer in situ. This displacement did not occur when tau was 
excluded (dark grey) and the plateau of the reaction occurred at a similar mP value as 
equimolar tauD421. Polarization (mP) is plotted for individual replicate samples in the 
experiment (n=3). Results are representative of three independent experiments G, 
Caspase-3 cleavage of tauFL induces tau ubiquitination (left panel). When CHIP is 
excluded from the reaction cleaved tauD421 accumulates but is not ubiquitinated (right 
panel). Results are representative of three independent experiments. 																			
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Figure S2.7. Caspase6D179 is bound and inhibited by CHIP. A, BLI confirmed that 
biotinylated WT CHIP coated sensors bound to caspase-6D179 (left panel, greyscale), 
but that no significant interaction was observed for sensors coated with biotinylated 
CHIPK30A at 1000 nM caspase 6 (right panel). Results are representative of three 
independent experiments B, In vitro ubiquitination of caspaseD179 showed that neither 
the large (L) or small (S) subunits were ubiquitinated in these conditions. (* denotes a 
contaminant band). Results are representative of three independent experiments C, 
CHIP inhibits the turnover of 12.5 μM Ac-VEID-AMC fluorogenic substrate by active 10 
nM caspase-6. This inhibition is not observed with CHIPK30A. Initial velocity V0 is plotted 
for individual replicate samples in the experiment (n=3). Data is representative of three 
independent experiments. 														
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Figure S2.8. CHIP mRNA is not downregulated in AD. A, A comparative analysis of 
CHIP mRNA levels (z-score) in RNAseq datasets from patients in the Allen Brain Atlas 
Aging, Dementia, and TBI dataset (http://aging.brain-map.org/) at Braak 0, I, II, III , IV, 
V, VI. There was no significant downregulation of CHIP mRNA in the four brain regions 
(Hippocampus, Parietal Neocortex, Temporal Neocortex, or White Matter). B, 
Comparison of CHIP mRNA z-score in patients +/- the ApoE4 allele also revealed no 
significant change in CHIP mRNA levels between the groups. C, Additionally, so 
significant variation of CHIP mRNA levels occurred with age. Significance was 
assessed by ordinary One-way ANOVA for Braak Stage and Age. ApoE4 dataset was 
analyzed using and unpaired t-test. 													
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Fig	4e	
	
Fig	5d	(top)*	
	
Fig	5d	(bottom)*	
	
	
Figure S2.9. Uncropped blots from main text figure 4e and 5d. *Blots from figure 5d 
include a replicate experiment not shown in the main text. 	
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Chapter 3 
 
Probing selectivity among TPR co-chaperones using peptide 
photoprobes 
Matthew Ravalin, Cory Nadel, Jason E. Gestwicki and Charles S. Craik 
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Abstract. The human proteome contains 273 proteins with an annotated TPR domain. 
Of these seventeen have been identified to be TPR co-chaperones that 1) co-
immunoprecipitated with cytosolic chaperones contain the conserved (M/I)EEVD motif 
at the extreme C-terminus and 2) contain a properly oriented carboxylate clamp to 
specifically engage the C-terminal aspartate present in this motif (Figure 3.2A). The 
discovery that the TPR co-chaperone CHIP engages in chaperone competitive 
interactions with proteins containing a C-terminal Asp establishes the possibility that all 
TPR Co-chaperones can engage in such interactions with explicit and latent C-termini. 
This observation increases the theoretical diversity of the PPI network anchored in TPR 
co-chaperone interactions by two orders of magnitude. The assessment of the 
selectivity of a given TPR binder will be critical to understanding the features of this PPI 
network. To this end we have developed a TPR foot printing platform that uses 
pernicious TPR binding sequences modified with an alkyl diazirine to covalently label 
available TPR binding sites in a cell lysate. Competition labeling experiments 
demonstrated that this platform could rank order candidate CHIP binders in a cell lysate 
and justify a transition to chemo-proteomic experiments to address TPR co-chaperone 
selectivity. 
 
1. Introduction. Photo-crosslinkers have found utility mapping protein-ligand and 
protein-protein interactions. Briefly, a protein or putative ligand is functionalized with a 
chemical moiety (usually a biphenyl acetone (BPA), azo-benzene, alkyl or aryl diazirine) 
through synthetic modification or metabolic incorporation.1 Each of these moieties is 
chemically inert in the absence of photo-stimulated uncaging of a reactive moiety. In the 
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case of the alkyl diazirine, exposure to light in the 330-370nm range generates an alkyl-
diazo intermediate that readily decays via the generation of molecular nitrogen and a 
reactive carbene. Canonically the carbene is capable of reacting with a wide array of 
functionalities present in biomolecules, although recent work indicates that the diazo 
intermediate may also covalently label carboxylic acids to form alky esters.2  
Regardless of mechanism, diazirine photoprobes have proven useful for mapping PPIs, 
identifying ensembles of metabolite binding proteins, target identification of natural 
products, and mapping ligandable sites in the proteome3–6.  
 Modern methods in mass spectrometry including stable isotope labeling by 
amino acids (SILAC) and tandem mass tagging (TMT) have made the quantitative 
comparative analysis of chemically modified and enriched proteomes tractable and 
multiplexable. More than a decade of work in this area has settled on an experimental 
paradigm wherein a high confidence interaction for a given bait is not determined by it’s 
ability to label a candidate prey but rater it ability to be competed specifically.7 This 
paradigm emphasizes the identification of high confidence interactions. This approach 
often results in the use of a promiscuous reactive moiety with the capacity to be 
visualized or enriched being used to footprint the specificity of competitors that lack the 
ability to be enriched (i.e do not contain an alkyne, azide, or other handle that can be 
used for affinity purification.). Borrowing form this paradigm we sought to develop 
promiscuous TPR photoprobes based on the sequences of Hsp70s and Hsp90s known 
to be critical for this interaction (IEEVD and MEEVD respectively). In this manner we 
could label all TPR co-chaperones and query candidate interactors against this 
background in a competitive paradigm. 
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2. TPR targeted photoprobes bind and label recombinant CHIP and HOP. Previous 
work from our lab and others indicates that while most TPR co-chaperones can bind to 
the Hsp70 derived IEEVD sequence as well as the Hsp90 derived MEEVD sequence, 
intrinsic preferences for one over the other are common.8 To ensure that we could 
maximize the probability of labeling as many TPR co-chaperones as possible we 
synthesized photoprobes containing a specificity element based on both sequences. In 
addition to the specificity element probes contained a lysine that was functionalized at 
the epsilon nitrogen with FITC (detection element) and an N-terminal 4,4’ azipentanoate 
(X-link) (Figure 3.1B). To assess the ability of the probes to bind to TPR co-chaperones 
we took advantage of the presence of the fluorophore and monitored the fluorescence 
polarization (FP) of the probe in a saturating binding experiment absent crosslinking. 
These experiments confirmed that the probes bound to both the E3 ubiquitin ligase 
CHIP and the scaffolding protein HOP (Heat-shock protein organizing protein) with 
relative affinities in line with previously reported values. 
 Given the apparent affinities of the photoprobes for CHIP and HOP we chose to 
incubate the proteins and photoprobes at a 1:1 ratio at 5uM. After pre-incubation probes 
were activated with a 40W LED array with an emission maximum at 365nM (see 
methods). Optimization experiments determined that labeling reached a maximum after 
10 min of exposure based on visualization by in-gel fluorescence after SDS-PAGE 
(Figure S3.1).  To confirm the specificity of labeling we co-incubated an 
unfunctionalized 10 amino acid peptide corresponding to the C-terminus of either Hsp72 
or Hsp90a at various concentrations to compete away the photoprobe and inhibit 
labeling. These experiments confirmed that both photoprobes (hv-(FAM)-70 and hv-
	 104 
(FAM)-90) were sensitive to the presence of a competing ligand when labeling both 
CHIP and HOP (Figure 3.1C and Figure 3.1D). Interestingly for HOP, competitors 
seemed, qualitatively, to be better at competing matched photoprobes (i.e. hv-(FAM)-70 
and Hsp72 or hv-(FAM)-90 and Hsp90a). This is in line with previous work that 
suggests that TPRs within HOP exhibit specificity between Hsp90s and Hsp70s. These 
experiments provided confidence that these probes would have utility in profiling a wider 
range of competitors in the more complex environment of a cell lysate. 
3. TPR photoprobes specifically label CHIP in cell lysate. To validate the of the 
photoprobes to specifically label TPR co-chaperones in the context of a cell lysate we 
generated a HEK 293T cell line that constitutively overexpressed CHIP with a C-
terminal FLAG tag (Figure 3.2A). Cell lysates were prepared and labeled with hv-
(FAM)-70 at 10 µM, hv-(FAM)-90 at 10 µM, or a 1:1 mixture of the two at 5 µM each and 
analyzed by on-membrane fluorescence in the absence and presence of photo-
crosslinking. To assess which bands corresponded to specific labeling events we also 
included competitors corresponding to the 10 C-terminal amino acids in Hsp72 and 
Hsp90⍺ (Figure 3.2B, top panel). This analysis identified two prominent bands that 
were labeled by the photoprobe and diminished in intensity in the condition containing 
competitor. The top band, with an approximate molecular weight of 75 kDa, was 
preferentially labeled by and competed by Hsp72 derived sequences. The other, with an 
approximate molecular weight of 37 kDa was competed by both Hsp72 and Hsp90⍺ 
derived sequences. Based on the molecular weight of the 37 kDa band it seemed likely 
that this was CHIP. This hypothesis was supported by the fact that a western blot with 
and anti-FLAG antibody overlaid with the 37 kDa band. To further confirm the specificity 
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of this labeling event photo labeled lysate was immunoprecipitated with anti-FLAG 
magnetic beads and subjected to a similar analysis (Figure 3.2C). These experiments 
confirmed that while CHIP-FLAG was enriched in all three conditions, labeling was only 
achieved upon exposure to light. Moreover, signal was competed away with excess 
peptide corresponding to the C-terminus of Hsp72. In total these results give us 
confidence that our probes are specifically labeling TPR co-chaperones in a cell lysate. 
4. TPR photoprobe competitions can rank order CHIP binders. A possible 
application for this technology is to compare the ability of a synthetic or endogenous 
ligand to compete for binding to a given TPR sequence. To gauge the sensitivity of the 
platform in this context we took advantage of the range of affinities of CHIP binding 
sequences at our disposal. Previous work (see Chapter 2) identified sequences other 
than Hsp70 and Hsp90 derived sequences that are able to compete for the CHIP 
interaction. One of these sequences corresponds to a neo-C-terminus generated by 
caspase cleavage of the microtubule associated protein tau (tau) cleaved at Asp 421 
(tauD421). The other, CHIPOpt (Ac-LWWPD) was determined to be an optimized 
acetylated five amino acid sequence for CHIP TPR binding. CHIPOpt competes for the 
chaperone binding site with a Ki roughly 50-fold lower than the Hsp70 derived 
sequence. To validate that the photoprobe platform could capture these differences we 
labeled CHIP-FLAG lysate in the presence of increasing concentrations of Hsp90a, 
Hsp72, tauD421, and CHIPOpt peptides ranging from .01 to 10 µM. These experiments 
shoed minimal competition of the CHIP band with Hsp90a and moderate competition 
with Hsp72 and tauD421 at the 10 µM concentration. However, CHIPOpt was capable of 
completely preventing labeling of the CHIP band at 1µM, 10 fold less than the 
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concentration of photoprobe (Figure 3.2D). These experiments demonstrate that the 
photoprobes are useful for rank ordering TPR binders and provide further support that 
CHIPOpt is a superior ligand for the CHIP TPR domain. 
5. Discussion and future directions. Based on the successful experiments discussed 
above we have high confidence that these photoprobes will prove useful for profiling the 
specificity of TPR co-chaperone binding sequences. In order to enable the affinity 
enrichment of labeled proteins we synthesized biotin functionalize (hv-(Bio)-70 and hv-
(Bio)-90) photoprobes analogous to the FAM functionalized probes. These probes were 
able to non-covalently compete with the FAM functionalized probe hv-(FAM)-70 fro 
CHIP binding with pKi of 5.8 and 5.1 for hv-(Bio)-70 and hv-(Bio)-90, respectively 
(Figure S3.2). Optimization of photolabeling parameters for these probes will be 
required to maximize the number of TPR co-chaperones engaged and enriched in a 
given cell lysate. If effective in this sense, these probes would be able to assess the 
probable TPR interactome of a given sequence in a single experiment. It may be 
possible to use recombinant or genetically encoded competitors in situations where 
peptides were undesirable. One could imagine using this technology in conjunction with 
the PSSCL platform described in Chapter 2 to iteratively identify new binders for a given 
TPR co-chaperone and subsequently characterize the TPR co-chaperone footprint of 
that sequence. In total we anticipate these platforms will synergize to enable a 
quantitative understanding of TPR co-chaperone PPI networks. 
6. Methods 
Protein purification 
CHIP was expressed and purified as described in chapter 2 (page 53) 
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HOP was purified as describe in Assimon et al 2015 
Peptide synthesis 
Peptide synthesis was conducted as described in chapter 2 (page 57) 
Functionalized photoprobes were synthesized by the incorporation of an orthogonally 
protected lysine (Fmoc-Lys(Mtt)-OH, EMD Millipore) in the 6th position relative to the C-
terminus. The diazirine was appended to the N-terminus using succinimidyl 4,4’ 
azipentanoate (SDA diazirine, Thermo Fisher Scientific). Diazirine capping was 
conducted with 1.7eq SDA diazirine and 20eq NMM in 500 µL DMF overnight at room 
temperature while shaking. After capping the Lys-MTT was deprotected with 500 µL 3% 
Trifluoroacetic acid in dichloromethane (DCM) 3x30min. Resin was washed 3x with 1mL 
DCM and allowed to dry on a vacuumed manifold. Resin was re-swollen in DMF for 
30min prior to modification of the deprotected lysine with either FITC as described in 
chapter 2 (page 57) or NHS-Biotin (EZ Link NHS-Biotin, Thermo Fisher Scientific). 
Reaction conditions for NHS biotin were identical to those for SDA diazirine. Peptides 
were cleaved, purified and characterized as described in chapter 2.  
Saturation binding and competition binding FP 
FP experiments were conducted as noted in chapter 2 (page 59) with the exception that 
experiments were conducted with 10 "M	tracer	and	read	on	a	SpectraMax	M5	plate	reader	
Crosslinking 
All crosslinking reactions were conducted in a PCR plate using a Tfscloin 40W UV LED 
Nail Dryer Lamp. Proteins were crosslinked at 10 uM. Cell lysates were crosslinked at 1 
mg/mL final protein concentration.  
Lysate preparation 
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All cell lysates were prepared using M-PER (Thermo Fisher Scientific) supplemented 
with cOmplete protease inhibitor tablet (Roche) as per the manufacturers instructions. 
Protein concentration was measured by BCA. Lysates were adjusted to 2 mg/mL and 
snap frozen in liquid nitrogen. 
SDS-PAGE 
See chapter 2 (page 64) 
In-gel fluoresence 
See chapter 2 (page 63) 
On-membrane fluorescence and western blotting 
50 µg of lysate was labeled for standard on membrane fluorescence experiments. After 
labeling proteins were precipitated with 9 volumes of cold acetonitrile and centrifuged at 
21,000 x g for 10 minutes. The solution was removed and the precipitate allowed to dry. 
The pellet was resuspended in 15 µL 1X SDS loading buffer, vortexed briefly and boiled 
prior to SDS PAGE.  For general transfer conditions and blotting conditions see chapter 
2 (page 64). CHIP Flag was detected using a rabbit anti DYKDDDDK antibody (Cell 
Signaling D6W5B) at 1:2000 in Licor blocking buffer. Licor anti rabbit 800 (1:10000) in 
Licor blocking buffer was used as the secondary. FAM and FLAG signal were detected 
sequentially using the 600 nm and 800 nm channels on the Licor Fc imaging system. 
Immunoprecipitation 
100 ug of HEK293T CHIP-FLAG Lysate was labeled for IP. After labeling, reaction was 
diluted to 300uL with M-PER and incubated for 1h with 25uL anti FLAG magnetic beads 
(Sigma) that had been washed 3X with 1mL M-PER After binding, Supernatants were 
removed and frozen. Beads were washed 5X w/ 1mL M-PER and Eluted with 40uL of 
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1X SDS PAGE loading buffer. 50 ug of Input (unlabeled lysate) and supernatants were 
precipitated as described above. On membrane fluorescence and western blotting were 
conducted as described above. 
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Figure 3.1. TPR photoprobes bind and label TPR co-chaperones in vitro. A, 
Cytosolic Hsp70s and Hsp90s engage in protein-protein interactions with a large 
network of TPR co-chaperones via a conserved interaction at a conserved motif 
(I/MEEVD) at the extreme C-terminus of the chaperone. B, Photoprobes containing a 
detection module, a crosslinking module (X-link), and a specificity module based on the 
C-terminus of Hsp70s (red) and Hsp90s) were synthesized to enable covalent labeling 
of TPR co-chaperones. C, Fluorescence polarization (FP) saturation binding 
experiments were used to determine the dissociation constant (Kd) of each photoprobe 
with CHIP and HOP. CHIP contains a one TPR domain and one Ubox domain in each 
protomer. The TPR coordinates the C-terminal Asp via a carboxy clamp formed by K30 
and K95 (yellow circles). Both hv-(FAM)-70 (left panel) and hv-(FAM)-90 (right panel) 
are capable of labeling CHIP. Both probes can be competed with noncovalent ligand in 
the form of a 10 amino acid peptide from either Hsp72(SGGPTIEEVD, top panel) or 
Hsp90a (DDTSRMEEVD, bottom panel). D, Hop contains a Three TPR domains and 
one. The TPRs coordinate the C-terminal Asp via a carboxy clamps formed by K8 and 
K73 (TPR1), K229 and K301(TPR2A), K364 and K429 (yellow circles). Both hv-(FAM)-
70 (left panel) and hv-(FAM)-90 (right panel) are capable of labeling CHIP. Both probes 
can be competed with noncovalent ligand in the form of a 10 amino acid peptide from 
either Hsp72(SGGPTIEEVD, top panel) or Hsp90a (DDTSRMEEVD, bottom panel). 
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Figure 3.2. TPR photoprobes specifically label CHIP in cell lysate. A, A schematic 
depicting the workflow for labeling TPR co-chaperones in cell lysate overexpressing 
CHIP-FLAG. Specific labeling events will be annotated based on the ability for a given 
labeling event to be competed non-covalently. In this way promiscuous probes can be 
used to characterize the specificity of candidate ligands. B, hv-(FAM)-70 (lanes 1,2) hv-
(FAM)-90 (lanes 3,4), or an equimolar mixture (lanes 5,6) were used to label HEK293T 
CHIP-FLAG cell lysates (10min hv exposure, lanes 2,4,5). Unexposed controls were 
included (lanes 1,3,5) in addition to conditions containing excess competitor (lane 7: 
Hsp72, lane 8: Hsp90a, lane 9 Hsp72+Hsp90a). Labeling was visualized after transfer 
to a nitrocellulose membrane (top panel). A western blot for CHIP-FLAG identified the 
CHIP band and detected a low level of crosslinking induced dimerization (middle panel). 
An overlay suggested that CHIP-FLAG was being labeled by both probes, and that 
labeling was competed by both competitors. C, A FLAG immunoprecipitation confirmed 
that CHIP-FLAG was specifically labeled, and that labeling could be competed with 
excess Hsp72 peptide. D, In-gel fluorescence was used to rank order the affinity of 
Hsp90a (DDTSRMEEVD), Hsp72 (SGGPTIEEVD), tauD421, (SSTGSIDMVD), and 
CHIPOpt (Ac-LWWPD). Competed bands are denoted with an asterisk (red). CHIPOpt 
was capable of competing with photoprobe at 1µM. 
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Figure S3.1. TPR photoprobe labeling time course. CHIP (top panels) or HOP 
(bottom panels) was incubated at a 1:1 ratio with hv-(FAM)-70 (left panels) or hv-(FAM)-
90 (right panels) and exposed to 365 nm light for various amounts of time ranging from 
0-10 min. Labeling was visualized by in-gel fluorescence. Coomassie stain was used to 
control for protein loading. 
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Figure S3.2. Biotin-TPR photoprobe competition binding to CHIP. A, Biotin 
functionalized photoprobes corresponding to Hsp70 (red) and Hsp90 (blue) tail 
sequences. B, Both the Hsp70 and Hsp90 probes are capable of competing with hv-
(FAM)-70 for CHIP binding with pKi of 5.8 and 5.1 respectively 
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